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Summary 
 
Inflammatory bowel disease (IBD), a common chronic inflammatory 
disorder of the gastrointestinal system, has been studied for decades. To 
clarify the pathogenesis of IBD and breakthrough the bottleneck of 
treatment remains a formidable task. It is widely acknowledged that 
inflammatory or tumor tissues exhibit elevated glucose uptake and local 
acidic pH due to hypoxia, excessive production and insufficient 
elimination of glycolytic metabolites. Recently, a novel family of proton 
sensing G-protein coupled receptors (GPCRs) including GPR4, ovarian 
cancer G protein coupled receptor 1 (OGR1, GPR68) and T-cell death 
associated gene 8 (TDAG8, GPR65) has been identified. All of these 
receptors are activated by protons in the physiological range around pH 
7.4. The intraluminal gastrointestinal pH in patients with active IBD is 
significantly decreased. Local acidification, as low as pH 2.3, has been 
observed during intestinal inflammation and implicated in the 
pathogenesis and progression of IBD. The role of proton-activated GPCRs 
in the pathogenesis of inflammation is mostly unknown.  
 
 
The aim of the thesis project is to unravel the relationship between pH 
receptors and IBD and to answer the question whether GPR4 and OGR1 
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may be involved in the pathogenesis of IBD. Here, we used two animal 
models to test our hypothesis; the dextran sulphate sodium (DSS) 
induced chronic colitis model and the IL10 KO mouse model, a 
spontaneous colitis model.  
 
DSS was used to induce chronic colitis in GPR4 knockout mice (Gpr4 -/-, in 
Balb/c and C57Bl/6 background) and their respective wild-type controls 
(Gpr4 +/+, in Balb/c and C57Bl/6 background), to resemble ulcerative 
colitis (UC). Mice in both groups received 4 cycles of DSS treatment,  
while additional control groups of both genotypes received only normal 
water. In each cycle, 3% DSS was administered for 7 days in drinking 
water followed by 10 days of recovery with tap water. Mice were 
sacrificed after 5 weeks recovery after the last DSS cycle. Body weight 
was monitored and colon samples were collected for histology, cytokine 
mRNA expression, and myeloperoxidase (MPO) activity quantification. 
The colonoscopy score, colon length, and spleen weight were also used 
to assess the severity of colitis. 
 
For the spontaneous colitis model, Ogr1 -/- and Gpr4 -/- mice (C57Bl/6) 
were crossed into interleukin-10 knockout (IL-10 -/-) mice (C57Bl/6), a 
spontaneous colitis model simulating Crohn's disease (CD), to generate 
Gpr4 +/+ /Ogr1 -/- /IL-10 -/- or Gpr4 -/- /Ogr1 +/+ /IL-10 -/- mice. The 
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development of rectal prolapse, a marker of severe intestinal 
inflammation, was followed over 200 days. The incidence of rectal 
prolapses in double knockout mice was compared with IL-10 -/- from the 
same litters. Kaplan-Meier survival analysis was introduced to evaluate 
whether deficiency of pH receptors could change prolapse occurrence. 
Moreover, to eliminate the bias and influence of severe colitis and 
development of prolapse, another group of mice was sacrificed at age 80 
days, before any of the mice developed prolapses. Severity of colitis was 
assessed by the conventional parameters cytokine mRNA expression, 
histological score, MPO activity, colon length, and spleen weight. Lamina 
propria leukocytes (LPLs) from large intestine in mice were freshly 
isolated and characterized by flow cytometry assay.  
 
After induction of chronic DSS colitis in Gpr4 +/+ and Gpr4 -/- mice, Gpr4 -/- 
mice showed less body weight loss (p <0.05 *) and lower histology 
scores (p <0.001 ***) indicating less severe inflammation. No significant 
difference in MPO activity and spleen weight was found. In the 
spontaneous colitis model, Kaplan-Meier survival analysis showed a 
significantly delayed onset and progression of rectal prolapses in female 
Gpr4 +/+ /Ogr1 -/- /IL-10 -/- mice relative to female Gpr4 +/+ /Ogr1 +/+ /IL-10 
-/- mice (p = 0.002 **) whereas there was no difference in male mice (p = 
0.776). In comparison with Gpr4 +/+ /Ogr1 +/+ /IL-10 -/- mice, both female 
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and male Gpr4 -/- /Ogr1 +/+ /IL-10 -/- mice had a significantly delayed 
onset and progression of rectal prolapses (estimated median survival 
time: female: >200 days vs. 123 days; male: >200 days vs. 161 days; p 
=0.000 *** and p =0.007 **). These findings were confirmed by the 
histology scores and MPO activity test.  
 
Our findings demonstrate that the deficiency of GPR4 attenuated colitis 
in the IL-10 -/- mice model. Because the spontaneous colitis in IL-10 -/- 
mice is mediated by T helper 1 (Th1) and T helper 17 (Th17) cells, we 
tested whetherin Gpr4 -/- /Ogr1 +/+ /IL-10 -/- mice the Th1, Th17 and T 
regulatory (Treg) subpopulation profile might differ from IL-10 -/- mice in 
lamina propria lymphocytes (LPLs). The LPLs profiles in flow cytometric 
analysis demonstrated that the deficiency of GPR4 suppressed 
infiltration of CD4+ (T helper) cells, mainly Th1 cells, but not CD8+ (T 
cytotoxic) cells, which was confirmed by the cytokine expression data. 
Female Gpr4 -/- /Ogr1 +/+ /IL-10 -/- mice had a significantly lower Th1 
cytokine IFN-γ mRNA expression in colon compared with their female 
Gpr4 +/+ /Ogr1 +/+ /IL-10 -/- counterparts.  
 
Taken together, these data suggested that GPR4 deletion in mice was 
followed by ameliorated colitis and reduced susceptibility in the DSS 
induced chronic colitis model and that the deficiency of both pH 
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receptors, either GPR4 or OGR1, attenuated spontaneous inflammation 
and modulated the severity of disease in the IL-10 -/- model. There data, 
therefore, indicate an important pathophysiological role for these 
G-protein coupled receptors during the pathogenesis of mucosal 
inflammation. 
 
In the end, a possible mechanism of GPR4-mediated inflammation 
aggravation is proposed. In the spontaneous colitis model, the additional 
deletion of GPR4 in IL-10 -/- mice leads to the loss of the proton sensors 
and defective downstream signaling pathway, induces suppression of 
Th1 cells and less production of IFN-γ in colon, offers protection and 
reduces spontaneous inflammation, and finally delays the onset and 
progression of rectal prolapse. Therefore, in turn, activation of GPR4 is 
likely to exacerbate intestinal inflammation and trigger responses which 
promote inflammation via a pathway involving Gs-cAMP, Th1, and IFN-γ.  
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ZUSAMMENFASSUNG 
 
 
Chronisch Entzündliche Darmerkrankungen (CEDs) befinden sich als 
häufige gastrointestinale Krankheitsentitäten seit Jahrzehnten im Fokus 
der Forschung. Es bleibt dennoch schwierig die Pathogenese vollständig 
zu erklären und die Entwicklung weiterer Behandlungsstrategien ist 
notwendig. Es gilt als gesichert, dass entzündetes sowie tumoröses 
Gewebe verstärkt Glukose aufnimmt und von einem sauren Milieu 
umgeben ist. Dies wird erklärt durch Hypoxie, eine exzessive Produktion 
von Glykolysemetaboliten mittels anaerober Glykolyse und einer 
insuffizienten Eliminierung dieser Metabolite.  
 
Kürzlich wurde eine neue Familie Protonen-aktivierter G-Protein 
gekoppelter Rezeptoren (GPCRs) identifiziert, welche GPR4, den Ovarian 
cancer G-protein coupled receptor 1 (OGR1, GPR68) sowie T-cell death 
asscociated gene 8 (TDAG8, GPR65) beinhaltet. All diese Rezeptoren 
werden durch Protonen innerhalb des physiologischen Bereichs um  pH 
7,4 aktiviert und könnten eine Rolle in der Aufrechterhaltung des pH 
Gleichgewichts spielen bzw in der Messung des lokalen pH.    
 
Messungen belegen, dass der intraluminale Darm-pH-Wert bei Patienten, 
welche an einem aktiven Schub einer chronisch entzündlichen 
Darmerkrankung leiden, signifikant saurer ist. Die pH-Wert Erniedrigung 
bis hin zu einem pH von 2.3 sind lokal auf den entzündeten 
Darmabschnitten begrenzt und es, ist anzunehmen, dass diese pH-Wert 
Veränderung in der Pathotgenese wie auch im Verlauf von CEDs eine 
bedeutende Rolle spielt. Die Rolle von Protonen-aktivierten GPCRs in der 
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Pathogenese von Entzündungen ist weitestgehend unbekannt.  
 
 
Ziel dieser Arbeit ist vornehmlich die Beantwortung zweier Kernfragen. 
Besteht ein Zusammenhang zwischen pH-Rezeptoren und CEDs und sind 
GPR4 sowie OGR1 an der Pathogenese von CEDs beteiligt?  Um unsere 
Hypothese zu überprüfen testeten wir zwei Mausmodelle. Einerseits das 
Dextransulphat  (Dextran Sulphat Sodium, DSS) induzierte chronische 
Kolitismodell und andererseits das spontane Kolitismodell in IL10 KO 
Mäusen. 
 
Mit DSS wurde in GPR4 knockout Mäusen (Gpr4 -/-, im Balb/c und 
C57Bl/6 Hintergrund) und Wildtyp Mäusen (Gpr4 +/+, ebenfalls im Balb/c 
und C57Bl/6 Hintergrund) eine Kolitis induziert, welche der humanen 
Kolitis Ulcerosa ähnelt. Während die Tiere in der Kontrollgruppe 
gewöhnliches Trinkwasser angeboten bekamen, erhielten die Tiere in 
beiden Versuchsgruppen eine Behandlung mit vier DSS-Zyklen. In den 
ersten sieben Tagen jedes Zyklus wurde dem Trinkwasser 3%iges DSS 
zugesetzt, gefolgt von zehn Erholungstagen mit normalem Trinkwasser. 
Die Mäuse wurden nach 4 Zyklen der 3%-DSS-Behandlung und einer 
abschliessenden fünfwöchigen Erholung getötet. Für die Evaluation der 
Krankheitsschwere wurde der Gewichtsverlauf protokolliert, ein 
Koloskopiescore erhoben und die Darmlänge sowie das Milzgewicht 
gemessen. Zudem wurden Kolonproben für die histologische 
Aufarbeitung entnommen und mRNA Level bestimmter Zytokine sowie 
die Myeloperoxidaseaktivität (MPO) bestimmt.   
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Für die spontane Kolitis wurden Ogr1 -/- und Gpr4 -/- Mäuse (C57Bl/6) 
jeweils mit Interleukin-10 knockout (IL-10 -/-, C57Bl/6) Mäusen gekreuzt 
um Gpr4 +/+ /Ogr1 -/- /IL-10 -/- bzw. Gpr4 -/- /Ogr1 +/+ /IL-10 -/- 
Doppelknockouts zu erhalten. Diese Tiere dienten als Modell für einen 
Morbus Crohn ähnlichen Krankheitsverlauf. Über einen Zeitraum von 
200 Tage wurde die Entwicklung eines Rektumprolaps als Indikator einer 
schweren intestinalen Entzündung erfasst. Die Inzidenz des 
Rektumprolaps in den Doppelknockout-Tieren wurde mit den IL-10 -/- 
Tieren aus der gleichen Zuchthaltung verglichen. Mithilfe der 
Überlebenszeitanalyse nach Kaplan-Meier wurde evaluiert ob ein 
Ausschalten derpH-Rezeptoren GPR4 oder OGR1 die Prolapsrate 
beeinflusst. Um die Pathogenese der Colitis zu einem Zeitpunkt zu 
vergleichen bei dem weder bei den Doppelknockout Tieren noch bei den 
IL-10 -/- Mäusen bereits ein Prolaps aufgetreten war, wurden weitere 
Mäuse im Alter von 80 Tagen getötet.. Zur Evaluation der 
Krankheitsschwere wurden die gewöhnlichen Parameter, herangezogen. 
Neben der Bestimmung des Histologiescores und der MPO-Aktivität 
wurde die mRNA Expression diverser Zytokine sowie die Kolonlänge und 
das Milzgewicht gemessen. Lamina propria Leukozyten (LPLs) aus dem 
Dickdarm wurden frisch isoliert und mittels Durchflusszytometrie 
charakterisiert.   
 
Nach Induktion der chronischen DSS Kolitis in Gpr4 +/+ und Gpr4 -/- 
Mäusen weist ein geringerer Gewichtsverlust (p <0.05 *) sowie ein 
niedrigerer Histologiescore in den Knockouttieren (p<0.001 ***) auf eine 
weniger schwere Kolitis hin. MPO-Aktivität und Milzgewicht 
unterschieden sich jedoch nicht signifikant. Im spontanen Kolitismodell 
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zeigte die Prolapszeitanalyse nach Kaplan-Meier ein signifikant 
verspätetes Auftreten von Rektumvorfällen in weiblichen Gpr4 +/+ /Ogr1 
-/- /IL-10 -/- Mäusen verglichen mit Gpr4 +/+ /Ogr1 +/+ /IL-10 -/- Mäusen (p = 
0.002 **). Dagegen konnte dieser Unterschied nicht in männlichen 
Tieren festgestellt werden (p = 0.776). Verglichen mit Gpr4 +/+ /Ogr1 +/+ 
/IL-10 -/- Mäusen, trat ein Rektumprolaps bei Gpr4 -/- /Ogr1 +/+ /IL-10 -/-, 
ungeachtet ihres Geschlechts, später auf (geschätzte mittlere 
Überlebenszeit: weiblich > 200 Tage vs. 123 Tage; männlich: >200 Tage 
vs. 161 Tage; p =0.000 *** and p =0.007 **). Unterstützt wird diese 
Beobachtung durch die Ergebnisse des Histologiescores sowie der 
MPO-Aktivitätsmessung.  
 
Unsere Untersuchungen konnten zeigen, dass eine GPR4 Defizienz eine 
Abschwächung der Kolitis im IL-10 -/- Mausmodell bewirkt. Die weiteren 
Untersuchungen konzentrierten sich auf die Klärung der 
zugrundeliegenden Mechanismen. Da die spontane Kolitis in IL-10 -/- 
Mäusen durch T1- sowie T17-Helferzellen (Th1 & Th17) unterhalten wird, 
testeten wir die Hypothese, dass sich Th1, Th17 und regulatorische 
T-Zellen (Treg) der Lamina propria Lymphozyten (LPLs) des Darms sich in 
Gpr4 -/- /Ogr1 +/+ /  IL-10 -/-- von Gpr4 +/+ /Ogr1 +/+ /IL-10 -/--Mäusen 
unterscheiden. Die LPLs Profile in der Durchflusszytometrieanalyse 
demonstrierten, dass die GPR4 Defizienz mit einer verminderten 
Infiltration CD4+ T-Helfer Zellen, vornehmlich Th1 Zellen, nicht aber 
CD8+ zytotoxischer T-Zellen einhergeht. Diese Ergebnisse wurden durch 
die Resultate der Zytokinexpressionsmessungen bestärkt. Weibliche 
Gpr4 -/- /Ogr1 +/+ /IL-10 -/- Mäuse wiesen eine signifikant niedrigere Th1 
INF-γ mRNA Zytokinexpression in Darmgewebe, verglichen mit den 
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entsprechenden weiblichen Gpr4 +/+ /Ogr1 +/+ /IL-10 -/- auf.   
 
Zusammenfassend weisen die Resultate darauf hin, dass der GPR4 
Knockout mit einer abgeschwächten Kolitis und einer reduzierten 
Anfälligkeit für die durch DSS induzierte Kolitis in Mäusen einhergeht. 
Das Fehlen der GPR4 oder OGR1 pH-Rezeptoren verbesserte die 
spontane Entzündung und modulierte die Krankheitsschwere im IL-10 -/- 
Modell. Zusammenfassend legen diese Daten eine bedeutende 
pathophysiologische Rolle der G-Protein gekoppelten Rezeptoren in der 
mukosalen Entzündung nahe.  
 
Abschliessend seien mögliche Mechanismen genannt, welche 
Erklärungsansätze für die GPR4-vermittelte Entzündung bieten. Die 
zusätzliche Deaktivierung von GPR4 in IL-10 -/- Mäusen führt zu einem 
Verlust von Protonensensoren und einem gestörten nachgeschalteten 
Signalweg. Sie bewirkt zudem eine Suppression von Th1 Zellen und eine 
geringere Produktion von IFN-γ im Darm. Letztlich stellt das Fehlen von 
GPR4 einen "Schutzfaktor" dar, der die Entwicklung einer spontanen 
Kolitis reduziert und das Auftreten sowie die Progression eines 
Rektumprolaps verzögert. Andersherum, deutet dies auf eine 
pro-inflammatorische Rolle von GPR4 und OGR1 in der Pathogenese von 
CED dar. Dies führt zu der Annahme, dass eine Aktivierung von GPR4 die 
Verschlechterung einer Kolitis bewirkt und  
entzündungsunterhaltenden Prozesse fördert.  
15 
 
 
 
 
 
 
 
 
 
 
 
Chapter 1 
Introduction 
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1.1 Inflammation and immune response 
 
1.1.1 Introduction 
 
What is the inflammation? “Inflammation is a protective response which 
intended to eliminate the initial cause of cell injury, as well as the 
necrotic cells and tissues resulting from the original insults” 1. The 
protection and elimination finally can be accomplished by diluting, 
destroying and neutralizing the harmful pathogens. These functions are 
mediated by a complex host response called inflammation 1.  
 
In general, the process of inflammation can be defined by the five “R” 2: 
(1) Recognition of the toxic pathogens, (2) Recruitment of leukocytes, (3) 
Removal of the agent, (4) Regulation of the response, and (5) Repairing 
of the tissue functions.  
 
In the initial step of protection, the innate immune system is activated by 
the chemical properties of the antigen, and it offers a fast and 
nonspecific defense mechanisms. These mechanisms include physical 
barriers such as physical (skin and mucosa), biochemical (i.e. 
complement, lysozyme and interferons), and immune system cells (e.g. 
neutrophils, monocytes, macrophages, natural killer [NK], and natural 
killer-T [NKT] cells) that attack foreign cells in the body 1. If the innate 
immune response is insufficient to facilitate the clearance of the foreign 
pathogen, the response will shift toward a more complex and efficient 
process – the acquired or adaptive immune response 3. The adaptive 
response recognizes the specific antigens through an antigen presenting 
process and enables B cell lymphocyte to mediate a humoral immune 
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response, whereas T cells lymphocyte mediate a cellular immune 
response 3.  
 
Due to the defense efforts of both the innate and the adaptive immune 
system, and all the immune cells and antibodies from the cellular and 
humoral immune responses, the toxic pathogens are removed from the 
body. Meanwhile, the repair process is started to fix the tissue functions. 
The repair process includes three different levels 4: regeneration, healing 
and/or fibrosis. Regeneration means new generations of tissues replace 
the damaged components and tissue functions essentially return to a 
normal state. If the injured tissue is not able to completely restitute, 
healing and fibrosis will provide enough structural stability that the 
injured tissue is usually able to function.  
 
Inflammation can be categorized into acute and chronic inflammation 1. 
Acute inflammation is rapid in onset and of short duration, lasting from a 
few minutes to a few days. In the context of acute inflammation, the 
main inflammatory reactions are composed of several vascular reactions 
and cellular responses 2: heat (color), redness (rubor), swelling and pain 
(tumor and dolor). The pathology of acute inflammation is characterized 
by vascular changes, edema, and predominant neutrophil infiltration. 
The outcome of acute inflammation is either elimination of the stimuli 
followed by returning of the host to the normal condition and repair of 
the tissue function, or persistent stimulation resulting in chronic 
inflammation if the stimuli cannot be eliminated immediately. The 
duration of chronic inflammation lasts from weeks to years. The 
prolonged host response to persistent stimulus can lead to continuous 
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immune cell recruitment and tissue damage. In pathology, chronic 
inflammation is characterized by tissue destruction; angiogenesis and 
fibrosis; infiltration with macrophages, lymphocytes and plasma cells. 
 
Although inflammatory reactions help clearing the stimuli, inflammation 
and subsequent repair processes themselves sometimes can cause 
substantial damage to the host body as well 1, 2, 4, 5. During severe 
inflammation, the host innate immune system mediates a strong 
reaction, e.g. damage and tissue destruction, in an attempt to clear the 
infections and other harmful stimuli, which exert a negative or 
irreversible effect on tissue functions. Injury also might be caused by 
auto-antigens in autoimmune diseases, or by harmless environmental 
antigens in allergic disorders.  
 
In short, the function of inflammation to the host body can be a 
double-edged sword. On one hand, it is a beneficial host response. On 
the other hand, it is itself capable of bringing tissue damage. In this 
sense, the immune system must be fine-tuned to maintain homeostasis.  
 
1.1.2  Th1 and Th2 cells in the adaptive immune system 
 
When the first line of defense (e.g. mucosa) is broken through, invasive 
bacteria will have to be eliminated by macrophages in their lysosome by 
endocytosis 3. And then, antigen presenting cells (APCs) (e.g. dendritic 
cells, macrophages and B lymphocyte) present the antigen peptides to 
the T cell receptor of T lymphocytes, thereby activating T cells. IL-1 
secreted by macrophages helps activating T helper cells (CD4+); whereas 
IL-2 secreted by activated T helper cells regulates proliferation and 
19 
 
differentiation of T helper 1 (Th1) and T helper 2 (Th2) subsets 6-10. Th1 
cells secreting IFN-γ and TNF- directly activate macrophages, nature 
killer cells (NK) and cytotoxic T cells (CD8+) 11, which are commonly 
known as cell-mediated immunity 3, 6, 9, 10. Th2 cells, primarily producing 
IL-4, induce proliferation and differentiation of B cells into antibody 
secreting plasma cells and memory B cells, which are called humoral 
immunity 3, 8, 12. Regulatory cytokines IFN-γ and IL-10 suppress Th2 and 
Th1 responses, respectively 3, 6-8, 10.  
 
 
Figure 1 Schematic overview of molecular interaction between 
cell-mediated and humoral immune responses 3. 
20 
 
 
Both cell-mediated and humoral immune responses constitute the 
adaptive immune system, the highly specific and sophisticated defense 
system, which allows humans to better cope with the hostile 
environment 3, 7, 8, 12. The cellular immunity protects the body by 
activating macrophages and natural killer cells, enabling them to destroy 
pathogens and form endosomes; by activating cytotoxic T cells that are 
able to induce apoptosis in tumor cells and virus infected cells; and by 
stimulating immune cells to secrete a variety of cytokines that 
up-regulate or down-regulate the function of other immune cells 
involved. The humoral immunity is also called the antibody-mediated 
system due to the production of specific antibodies 3, 12. The plasma cells 
produce huge amounts of antibodies that will bind to the antigens and 
drive the target microorganisms for destruction. B memory cells remain 
the "memory" for the specific antigen that can be used to mobilize the 
immune system faster if the body meets the antigen later again 12.  
 
It should be emphasized that Th2 cells, bridging the gap between T and B 
cells (Figure 1), are essential to stimulate IgE production 3, 6, 9, 12. The 
humoral immunity will not be activated in the absence of Th2 cells, 
which is why the cellular cooperation between T and B cells is required 
for the production of antibodies. 
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1.1.3 Overview of Th1, Th2, Th17 and Treg   
 
 
 
Figure 2 The cytokine environment during antigen presentation controls 
T-cell differentiation by regulation of specific transcription factor 
activation 5. 
 
Based on the array of cytokines (e.g. IFN-γ or IL-4) produced by T 
lymphocytes, T helper cells are classically grouped into Th1 and Th2 cells 
subsets 6-10. More recent studies have further broadened our knowledge 
of T cells. Nowadays, immunologists generally acknowledge that T helper 
cells are not restricted to Th1 and Th2 cells. A new subset of T cells (Th17) 
13, which are characterized by producing IL-17 and IL-22, but not IFN-γ or 
IL-4, emerged to mediate chronic inflammatory disorders in 
collaborations with Th1 and Th2 cells 14, 15. These three T helper cells 
(Th1, Th2 and Th17) have also been called T effector cells (T effector) 6-11, 
13.  
 
T effector cells are able to generate an antigen specific T cell immune 
response to eliminate antigens 9. But, uncontrolled or excessive immune 
responses can lead to continuous inflammatory cell recruitment and 
tissue damage too, if persistent and unregulated, can finally result in 
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organ dysfunction. There must be some ways to control or prevent 
auto-immune responses. Besides the anti-inflammatory cytokine IL-10, T 
regulatory (Treg) cells are present as inhibitors and suppressors of the 
immune responses 16, 17, which are characterized by the high and stable 
expression of CD25+ and FoxP3 18, 19. The in-vivo animal models provided 
some evidence for the presence and functions of Treg. The complete 
Treg depletion in Treg knockout mice led to profound autoimmunity and 
lethal autoimmune disease, which demonstrates that Treg suppression 
plays an indispensable role in the immune homeostasis 20.  
 
In general, T cell differentiation is a complex process, depending on the 
local cytokine environment and the regulation of specific transcription 
factor activation. Figure 2 shows how Naïve CD4+ T cells can be 
differentiated into 3 effector T cells and Treg cells subgroups 5. In Th1 
pathway, IL-2 and IL-12 induces Th1 differentiation, which promotes 
cell-mediated Th1 response. Compared with antibody-mediated Th2 
response, Th1 response characterized by IFN-γ production along with 
T-bet transcription factor expression, is a more effective and stronger 
response 3. But, long term of Th1 response will be devastating to the 
host, and the immune response therefore must be shift to a relatively 
mild response for the tissue. That is Th2 response, which requires GATA3 
transcription factor expression 5. In terms of Th17, Th17 differentiation 
depends on the expression of RORγ+ transcription factor and the 
exposure to transforming growth factor β (TGF-β) 5, 13. While Treg 
pathway, as the above picture shows, relies on the expression of 
transcription factor FoxP3 plus TGF-β 16, 17. All these four T cell subtypes 
are major components of immune systems. 
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1.2 Inflammatory Bowel Disease (IBD) 
 
1.2.1 A Brief Introduction to IBD 
 
Inflammatory Bowel Disease (IBD) 21-24 is a chronic disorder and 
inflammation of the colon and small intestine characterized by 
abdominal pain, vomiting, diarrhea, intestinal bleeding, anemia, body 
weight loss and various associated complaints or diseases like 
rheumatoid arthritis (RA), sclerosing cholangitis, ankylosing spondylitis, 
iritis/uveitis, pyoderma gangrenosum and erythema nodosum 25. 
 
IBD is conventionally divided into two major types: Crohn's disease (CD) 
and ulcerative colitis (UC). The main difference between Crohn's disease 
and Ulcerative colitis is the location and nature of the inflammation 
(Figure 3) 26. Crohn's disease may affect any part of the gastrointestinal 
tract, from mouth to anus, in spite of the majority of the cases starting in 
the terminal ileum. Ulcerative colitis, in contrast, is restricted to the 
colon and the rectum. Histologically, ulcerative colitis is restricted to the 
mucosa (epithelial lining of the gut), while Crohn's disease affects the 
whole bowel wall 23, 24.  
 
1.2.2 Epidemiology 
 
It is estimated that as many as 1.4 million people in the United States 
and 2.2 million in Europe are suffering from IBD, based on a study in 
2004 27. IBD’s peak onset is in persons 15 to 30 years of age. There seems 
to be slight gender related differences in IBD incidence. Ulcerative colitis 
is slightly more common in males, whereas Crohn’s disease shows a 
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slight female predominance 27.  
 
 
Figure 3 Features for differentiating between UC and CD 26 
 
1.2.3 Pathogenesis of IBD 
 
There are two major hypotheses on IBD pathogenesis 28, 29: 1. IBD is 
caused by abnormal and excessive immunological responses to the 
normal intestinal microflora. For example, the disorders of the mucosal 
innate immune system cause IBD, caused by events such as NOD2 
polymorphisms, functional disorders of NOD2 or defective NOD2/CARD 
15 signaling pathways.  2. IBD is alternatively caused by primary 
abnormal changes in the intestinal microflora. The changes in the 
composition of intestinal microflora result in pathogenic responses and 
mucosal inflammation. For instance, many IBD mouse model exhibit the 
features of bacteria driven inflammation, supporting the latter 
hypothesis. Being such a complex, chronic and relapsing disorder, to 
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clarify the pathogenesis of IBD remains a formidable task, however 21-25. 
Both hypotheses require further evaluation and validation 28, 29. 
 
1.2.4 The intestinal mucosal immune system 
 
The intestinal mucosal immune system is composed of three major 
lymphoid areas (Figure 4) 30, 31: 1. Lamina propria lymphocytes (LPLs), 
which lie beneath the epithelium and the basement membrane in the 
intestinal villi, constituting the mucosa with the epithelium; 2. 
Intraepithelial lymphocytes (IELs), which locate between the columnar 
epithelial cells; 3. Peyer’s patches (PP), which are embedded in the gut 
wall. These three parts (LPLs, IELs and PP) constitute a complex network, 
the gut-associated lymphoid tissue (GALT), to respond to pathogens and 
insults in the gastrointestinal (GI) system.  
 
Obviously, the intestinal epithelium within the GI tract plays a key role in 
the homeostasis maintenance of the intestinal immune system. Intestinal 
epithelial cells form a physical barrier against the massive invasion of 
bacteria and other antigens. An intact mucosal barrier and its integrity 
depend on intercellular tight junctions between cells, which help seal the 
paracellular space.  
 
Under normal conditions 21, 22, the mucus layer secreted by the goblet 
cells, antimicrobial peptides (e.g. α-defensins) secreted by the paneth 
cells and IgA provide enough protection against bacterial invasion. In IBD 
21, in contrast, the immune responses damage the mucus layer, reduce 
the production of antibodies and defensins, and increase the exposure to 
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luminal bacteria.  
 
Under normal circumstances 21, 22, the initial immune response to 
intestinal bacteria is precisely regulated, and the regulation mechanism 
will decide whether there will be immune tolerance or triggering of a 
defensive response. Pattern recognition receptors, such as toll like 
receptors, and nucleotide oligomerization domain (NOD) like receptors 32, 
sensing NOD proteins, are essential to identify innate microbial signals 
and pathogen-associated molecular patterns (PAMPs). And then 
dendritic cells present antigens to naïve CD4+ T cells in PP and drive the 
differentiation of CD4+ T cells into regulatory T cells (Treg) and  T helper 
cells (Th1, Th2 and Th17) with the assistance of cytokines, e.g. 
transforming growth factor β (TGF-β) and interleukin 10 (IL-10). The 
mentioned subtypes of CD4+ T cells together with specific cytokines 
circulate to the intestinal lamina propria area and carry out effector 
functions (Figure 4) 21, 22. 
 
The intestinal mucosal immune system forms a complex network 33. 
Normally, the innate and adaptive immune cells in thelamina propria 
secrete a variety of cytokines, including anti-inflammatory cytokines, e.g. 
TGF-β and IL-10, which suppress the immune responses, and 
pro-inflammatory cytokines, e.g. tumor necrosis factor-α (TNF-α), IL-1β, 
IL-6, IL-12 and IL-23, which limit the exposure to luminal bacteria and 
protect the epithelium cells and tight junctions against toxic pathogens. 
Meanwhile, the regulatory T cells (Treg) and effector T cells subgroups 
(Th1, Th2 and Th17) are believed to hedge with each other by their 
cytokines and chemokines 21. The balance between Treg and effector T 
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cells subgroups (Th1, Th2 and Th17) are tightly regulated to maintain the 
intestinal homeostasis as mentioned before 6, 7, 9. 
 
In IBD, on the one hand, due to the continued epithelium injury, the 
integrity of the mucosal barrier is broken and the permeability through 
epithelial cells is substantially increased, causing defective regulation of 
tight junctions, increasing bacteria invasion and the significant 
amplification of the immune responses (Figure 5B) 21. On the other hand, 
the intestinal homeostatic equilibrium is completely disrupted during IBD. 
Innate cells in IBD produce increased levels of pro-inflammatory 
cytokines, TNF-α, IL-1β, IL-6, IL-12 and IL-23 33. These cytokines 
accelerate the differentiation/activation of effector T cells subgroups 
(Th1, Th2 and Th17) and bring the inadequate suppression of Treg 34. The 
marked expansion and proliferation of the lamina propria area is 
accompanied by intensive helper T cells infiltration, especially 
pro-inflammatory T cells subpopulations (Th1 and Th17) 13, which 
significantly exacerbate the inflammatory responses, and additional 
leukocyte recruitment by chemokine attraction, ultimately form an 
inflammation cycle (Figure 5B) 21, 22.  
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Figure 4 The intestinal mucosal epithelium cells and innate immune 
recognition under normal circumstances 21.   
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Figure 5 The intestinal mucosal immune system in normal condition (A) 
and in IBD (B). The picture was taken from 21. 
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1.2.5 CD is a Th1/Th17 response and UC is a Th2-like response 
 
 
Figure 6 The basic dichotomy of cytokine secretion profiles in CD and UC 
35, that means CD is a Th1/Th17 response and UC is a “Th2 like” response. 
 
The helper T cells are differentiated into Th1 and Th2 cells, characterized 
by different cytokine secretion profiles, e.g. IFN-γ and IL-4 respectively 6, 7, 
10. From this angle, a new classification scheme that CD differs from UC 
was quickly established, in which CD seemed to be a Th1/Th17 response 
driven disease whereas UC seemed to be a Th2-like response (Figure 6).  
 
In the new classification scheme 35, CD is dominated by the production of 
IFN-γ and IL-12/IL-23, looking like a Th1/Th17 response. UC, in contrast, is 
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driven by a “Th2-like” response with the normal IFN-γ production. The 
dendritic cells in UC present their antigens to NKT cells and induce the 
production of the cytokines IL-13 and IL-5, which primarily play 
pro-inflammatory roles. Because another signature cytokine IL-4 from 
Th2 cells is not increased in UC, it is better to call UC a ‘Th2-like” 
response rather than an absolute Th2 response 35.  
 
The concept of distinguishing CD and UC undoubtedly contributes to our 
better understanding of the fundamentals of disease and pathogenesis. 
But the division between CD and UC is not so absolute, it still awaits 
further studies to prove and develop 35. 
 
 
1.2.6 Overview of susceptibility loci implicated in IBD by GWAS 
 
Our current knowledge of IBD mainly stems from the combination of 
clinical studies, in vivo mouse model studies and genome-wide 
association studies (GWAS) 36. In the past decade, GWAS has been 
proven to be a powerful tool for geneticists and biomedical researchers 
to discover susceptibility genes, opening a door to potential treatments 
by unveiling the unexpected functional and mechanistic pathways in 
disease processes 37. 
  
In detail, GWAS, using large case control samples and several hundred 
thousand genetic markers, uncover new genomic regions/locations (loci) 
associated with a given trait such as the susceptibility to complex 
diseases 37, such as IBD.  In contrast with single gene disorders, complex 
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disease is usually caused by many genetic and environmental factors 
working together, each having a relatively small effect but leading to 
onset of the disease if interacting with each other 38.  
Table 1 Loci or genes detected by genome-wide association scans in IBD 
36. 
IBD related processes 
Epithelial barrier GNA12*,HFA4A,CDH1,ERRFL1, MUC19, ITLN1* 
Restitution REL,PTGER4,NKX2-3,STAT3,ERRFI1, HNF4A, PLA2G2A/E 
Solute transport SLC9A4, SLC22A5, SLC22A4*,AQP12A/B, SLC9A3, SLC26A3 
Paneth cells ITLN1*, NOD2*, ATG16L1*, XBP1* 
Innate mucosal defense NOD2*, ITLN1*, CARD9*,REL, SLC11A1, FCGR2A*/B 
Immune cell recruitment CCL11/CCL2/CCL7/CCL8, CCR6, IL8RA/IL8RB, MST1* 
Antigen presentation ERAP2*, LNPEP, DENND1B 
IL-23/Th17 IL23R*, JAK2, TYK2*, STAT3, ICOSLG, IL21, TNFSF15* 
T-cell regulation 
 
NDFIP1, TNFSF8, TAGAP, IL2, IL2RA,TNFRSF9, PIM3, IL7R*, 
IL12B, IL23R*,PRDM1, ICOSLG, TNFSF8, IFNG, IL21 
B-cell regulation IL5, IKZF1, BACH2, IL7R*, IRF5 
Immune tolerance IL10, IL27*, SBNO2, CREM,IL1R1/IL1R2, NOD2* 
  
Cellular responses 
Autophagy ATG16L1*, IRGM, NOD2*,LRRK2, CUL2, PARK7, DAP 
ER stress CPEB4, ORMDL3,SERINC3, XBP1* 
Intracellular logistics VAMP3, KIF21B, TTLL8,FGFR1OP, CEP72, TPPP 
Cell migration ARPC2, LSP1, AAMP 
Apoptosis/necroptosis FASLG, THADA*,DAP, PUS10, MST1* 
Carbohydrate metabolism GCKR*, SLC2A4RG 
Oxidative stress 
 
PRDX5, BACH2, ADO, GPX4, GPX1*, SLC22A4, LRRK2, 
NOD2*, CARD9*, HSPA6, DLD, PARK7, UTS2*, PEX13 
 
Recent advances in GWAS have provided substantial insight into the 
maintenance of mucosal homeostasis and the pathogenesis of IBD, 
which re-define and revolutionize our knowledge 36. So far, GWAS and 
Meta analysis from IBD have successfully identified 99 non-overlapping 
genetic risk loci 36, 39-41. Among those loci, 71 were reported in CD and 47 
were reported in UC, including 28 risk loci which are shared between CD 
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and UC 36, 39-41. The genetic risk loci and corresponding genetic variants 
suggest the importance of innate immunity, autophagy and phagocytosis 
in the disease susceptibility. 
 
Comprehensive analysis of the risk loci and candidate genes discloses 
several pivotal steps in intestinal homeostasis (Table 1) 36, including ① 
innate immune system functions: epithelial barrier, epithelial restitution, 
solute transport, Paneth cells and secretion of defensins, innate mucosal 
defense; ② adaptive immune system functions: immune cell recruitment, 
antigen presentation, IL-23/Th17, T-cell regulation, B-cell regulation, and 
immune tolerance; ③ cellular responses: autophagy, endoplasmic 
reticulum (ER) stress, intracellular logistics, cell migration, 
apoptosis/necroptosis, carbohydrate metabolism, oxidative stress and 
reactive oxygen species (ROS) generation (Table 1).  
 
Interestingly, in a recent GWAS effort, T-cell death associated gene 8 
(TDAG8, GPR65), one of the members of the proton sensing receptor 
family, has been identified as a susceptibility gene and risk locus in CD 
(Table 2) 40, 41.  
 
 
Table 2 The representative confirmed Crohn’s disease risk loci and 
corresponding odds ratios 40, 41. 
dbSNP ID Chromsome Gene Name Odds ratio (95% CL) Amino acid substitution 
rs8005161 14q35 GPR65/TDAG8 1.23 (1.16~1.31) IIE 231 LEU 
rs11209026 1p31 IL23R 2.66 (2.36~3.00) ARG 391 GLN 
rs2076756 16q12 NOD2 1.53 (1.46~1.60) -- 
rs3024505 1q32 IL-10 1.12 (1.07~1.17) -- 
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The potential for variants identified in GWAS to predict the risk of 
complex disease has been expected, but the application is still 
controversial. And the confirmation of loci’s role and causality awaits 
detailed fine-mapping, expression and functional studies 38-41.  
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1.3 IBD and acidic pH 
 
1.3.1 Inflammation and acidic pH 
 
In the human body, most acids come from carbohydrate and fat 
metabolism, which generates huge amounts of CO2 accompanied with 
the ATP generating and aerobic respiration. Then, CO2 dissolves in the 
water to create carbonic acid (H2CO3) and dissociates into H+ and HCO3− 
42.  
 
CO2 + H2O    (H2CO3)    H+ + HCO3−  
 
Normally acid base balance is maintained by intracellular and 
extracellular buffering and by the pulmonary and renal systems 42. 
Higher H+ concentrations drive the equation back to the left and 
generate more CO2. In turn, overproduction of CO2 pushes the equation 
forward to the right side and creates a more acidic environment. 
Hereinto, CO2 concentration is tightly controlled by pulmonary 
ventilation, and H+ and HCO3− density could be finely controlled by renal 
elimination and regeneration of bicarbonate 42. 
 
In clinical practice, acid based disorders can be divided into two 
categories 43: isocapnic acidosis (e.g. metabolic acidosis caused by 
excessive metabolic acids) and hypercapnic acidosis (e.g. respiratory 
acidosis due to carbon dioxide accumulation). The major reasons for 
isocapnic acidosis include: increased acid production, acid ingestion, and 
decreased renal acid excretion (e.g. kidney failure), GI or renal HCO3− loss 
(e.g. diarrhea or taking carbonic anhydrase inhibitors). The reasons for 
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respiratory acidosis are decreased ventilation and chronic obstructive 
pulmonary disease 42. 
 
During inflammation, the following factors contribute to extracellular 
local acidification 44-48 :  
 
1. The hypoxia and ischemic condition in inflammed tissues and high 
level of metabolic activity of immune cells in acute or chronic 
inflammation result in a switch to anaerobic glycolysis and 
subsequent accumulation of lactate and glycolytic metabolites, finally 
inducing lactic acidosis.  
2. The massive infiltration of leukocytes, mainly neutrophil and 
macrophage, produce huge amount of protons during the activation 
of the respiratory burst. Meanwhile myeloperoxidase (MPO) uses the 
reactive oxygen species hydrogen peroxide (H2O2) to produce 
abundant hypochlorous acid. 
3. The accumulation of short chain fatty acids, particularly succinic acid, 
which are the by-products of microbial metabolism in inflammatory 
tissues, reduces intracellular pH and impairs superoxide and hydrogen 
peroxide by inhibiting neutrophil respiratory burst. 
4. As mentioned before, in respiratory infections, decreasing CO2 
ventilation aggravates the acidosis. Or in the condition of colitis and 
diarrhea, vast HCO3− loss does the same job. 
 
Just as inflammation can induce local acidification or in severe sepsis also 
acidosis, in turn, acidic environment worsen the inflammation and 
aggravate the inflammatory response through immune cells (Figure 7). It 
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has been reported that low extracellular pH induces the activation of 
neutrophils and accelerated the maturation of dendritic cells 44-48. 
Extracellular acidification was found to induce human neutrophil 
activation by a mechanism dependent on the activation of P13K/Akt and 
ERK pathways, and low pH intensifies acute inflammatory responses by 
delaying spontaneous apoptosis of neutrophils and extending the 
neutrophil functional lifespan 44, 45. And the work from same group 
proved that extracellular acidosis increased endocytosis by dendrictic 
cells (DCs) and improved the antigen presenting ability by upregulating 
expression of cell surface proteins involved in antigen presentation and 
promoting the efficacy of MHC class-1 restricted antigen presentation 46, 
47. The transient exposure of human dendritic cells to pH 6.5 significantly 
improved its antigen presenting ability and activated the P13K/Akt and 
MAPK pathway via a strict p38 MAPK dependent manner. Interestingly, 
DCs exposure to pH 6.5 also induces a dramatic increase in the 
production of IL-12 and IFN-γ, but not IL-4, favoring a Th1 immunity 
pathway 48.   
 
For other immune cells, e.g. monocytes, low extracellular pH (pH 6.5) 
stimulates the production of IL-1β by human monocytes through a 
caspase-1 dependent pathway, but not affecting the production of other 
pro-inflammatory cytokines such as TNF-α and IL-6 49. Rubartelli et al 
reported the same association that acidic extracellular pH (pH 5.7) 
stimulated IL-1β production while alkaline extracellular pH (pH 8.2) 
reversed this process 50. The authors imply that extracellular acidosis 
induced activation of immune cells might derive from the activation of 
specific proton sensors expressed in these immune cells 50.  
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Inflammation in acidic conditions     Acidosis in inflammatory conditions 
 
Figure 7 The relationship between acidosis and inflammation, adapted 
from 51. An overview of clinical conditions characterized by tissue 
acidosis and hypoxia that causes inflammation (left) and inflammatory 
diseases leading to tissue acidosis and hypoxia (right).  
 
1.3.2 IBD and acidosis 
 
The tissue and blood pH is maintained in a range around pH 7.4 mainly 
through regulation of respiration and renal acid extrusion 42. In contrast, 
the luminal pH value in the normal gastrointestinal tract shows a 
progressive increase in pH from the duodenum to the ileum, and a 
decrease in the caecum, and finally a slow rise again along the colon to 
the rectum (Figure 8).  
 
Very interesting, Fallingborg et al reported that intraluminal colonic pH 
values in patients with active UC were significantly lower than in normal 
subjects 52. In his study, intraluminal gastrointestinal pH was measured by 
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the radiotelemetry capsule method in seven patients with active UC. 
Three out of seven patients showed very low pH levels (lowest values 2.3, 
2.9, and 3.4) in the proximal parts of the colon (Figure 9). Another three 
patients showed normal pH values in the colon 52. Whereas, all of these 
pH levels were normal in the stomach and small intestine other than 
colon, suggesting lower pH value might be an indicator of severe disease 
activity of the colitis. Raimundo et al reported similar findings (luminal 
pH as low as 4.7 in right colon) in patients with both active and inactive 
UC 53. Nugent et al also reported colonic luminal pH value dropped to 
less than 5.5 in two of six patients with active UC 54.  
 
 
Figure 8 Gastrointestinal pH profile of the normal subject. The picture 
was taken from 55 and was modified to indicate pH range. 
 
For CD patients, in one study in 1997, acidic colonic luminal pH was 
found similar as  in active UC patients. Three out of four CD patients 
had lower pH values in the right (pH 5.3) and left colon (pH 5.3) than 
normal controls (pH 6.8) 54. The authors also suggested that the reduced 
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intracolonic pH impaired bioavailability of 5-ASA (5-aminosalicylic acid, 
medication for IBD) in a pH dependent manner and substantially affected 
the efficacy of pH dependent colonic release and absorption of drugs 54. 
These data indicated the pH controlling system in the gastrointestinal 
system may correlate with the IBD occurrence and intraluminal pH levels 
might be an indicator of severity of IBD. 
 
Nevertheless there are still some discussions on the range of the 
intestinal luminal pH in IBD patients 56-58. 
 
 
Figure 9 Gastrointestinal pH profile of a patient with active UC 52. 
Shadow area represents mean values in healthy subjects. St: stomach, C: 
cecum, Asc: ascending colon, Tr: transverse colon, Des: descending colon, 
S/R: sigmoid colon and rectum. The study demonstrates that very low 
intraluminal pH levels in the colon occur in a patient with active 
ulcerative colitis. This might be an indicator of severe activity of the 
disease. A radiotelemetry capsule was used, and its location was 
determined by fluoroscopy. 
 
First, whether or not the intestinal luminal pH in IBD patients is more 
acidic is still controversial in the academic community. Press et al 56 
reported the right colonic luminal pH in 11 patients with active UC (mean 
values7 - 7.19), which are higher than those in normal controls (mean 
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value 5.88). Similarly, the left colonic luminal pH in UC patients was 
slightly higher than in normal controls too. Ewe et al 57 also stated 
inflammation did not decrease intraluminal pH in IBD, and that the 
median pH in the terminal ileum of patients with CD was 7.5 vs. 7.7 and 
in the rectum in UC 7.8 vs. 7.2 in the controls. 
 
Second, we cannot rule out the influence of diets and dietary patterns 
changing  luminal pH values due to the onset of IBD 58. Diet significantly 
affects gut pH. For example, the increased intake of dietary fiber would 
aggravate acidosis by providing a carbohydrate meal to colonic flora 59, 60. 
The hydrogen and bicarbonate ion secreted by intestinal mucosa are the 
major determinants of the normal luminal pH. Other factors involved are 
lactate production, bacterial fermentation of carbohydrates and mucosal 
absorption of short chain fatty acids. During severe inflammation, 
reduced mucosal bicarbonate secretion, increased bacterial lactate 
production, and decreased short chain fatty acids might also contribute 
to the low pH in IBD patient’s colon 59, 60.  
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1.4 Proton Sensing Receptor Family 
 
The receptors GPR4 and OGR1 (ovarian cancer G protein coupled 
receptor 1, GPR68) were identified about 15 years ago during the efforts 
to clone novel G protein coupled receptors 61. TDAG8 (T-cell death 
associated gene 8, GPR65) acting as an upregulated gene after 
glucocorticoid treatment of T cells was identified in 1996 62. All of the 
three receptors share a high similarity at amino acid level (Figure 10). 
The three GPCRs were originally characterized as a protein group 
regulating physiological responses to the lipid messengers 
Sphingosylphosphorylcholine (SPC) and Lysophosphatidylcholine (LPC) 
and psychosine. But the key evidence publications have been retracted 
since 2005 63-67. In contrast, accumulating evidence showed that all three 
GPCRs (GPR4, OGR1 and TDAG8) are activated by protons in the 
physiological range around pH 7.4 and may play a crucial role in pH 
homeostasis 61, 68.  
 
 
Figure 10 The receptor backbone model for OGR1, GPR4 and TDAG8, 
with all histidines residues highlighted 61. Structural studies of three pH 
receptors (in silico modeling) suggested that histidines residues (ball-like 
structures) in all three receptors may play a pivotal role in proton binding 
and pH sensing. The hypothesis was confirmed by site-directed 
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mutagenesis studies in OGR1 61, 68. 
 
The three pH-sensing receptors seem to be relevant for physiological 
process developed in later evolution because they are found in 
mammalian species and vertebrates including Xenopus, Fugu, zebrafish 
and chicken, but not in Drosophila, C. elegans, or plasmodium 61. In 
humans, OGR1 mRNA shows a low abundance in a wide range of tissues 
but is significantly highly expressed in lung, gastrointestinal tract, kidney, 
bone, and the nervous system. GPR4 shows significantly high abundance 
in endothelial cells despite it also is found in kidney, white adipose tissue, 
and lung. Very interesting, TDAG8 appears to be restricted to the 
immune system and bone, including peripheral blood leukocytes, spleen, 
lymph nodes, thymus, and osteoclasts which may play biological roles in 
the immune response and bone remodeling during local or systemic 
acidosis 62, 69, 70. 
 
A more detailed recent analysis from Dr. Klaus Seuwen’s lab (Novartis 
Institute for Biomedical Research) showed that the proton-activated 
receptor OGR1 acts via the Gq pathway and results in IP3 formation and 
calcium mobilization in OGR1 overexpressing cells. OGR1 is inactive at pH 
7.8 and fully activated at pH 6.8. Half maximal activation of the IP3 
formation by OGR1 expressed in CCL39 cells occurred at pH 7.48 68. For 
GPR4 and TDAG8, activation is through the Gs pathway and intracellular 
cAMP accumulation 61, 69, 70. Half maximal activation of cAMP formation 
by GPR4 expressed in HEK293 occurred at pH 7.53. The pH sensing 
properties of TDAG8 were independently reported by two Japanese 
groups 69, 70. Both groups stated that the TDAG8 receptor is a proton 
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sensing receptor and responsive to extracellular pH changes. But, in 
regard to psychosine, there is a dispute over its function as a ligand or 
antagonist. One group insisted that psychosine can bind to the TDAG8 
receptor and that psychosine can exert an inhibitory effect on receptor 70. 
Another group argued that psychosine did not stimulate or inhibit cAMP 
formation at all 69. However, the data from these experiments with 
several TDAG8 transfected cell lines showed cAMP was markedly 
accumulated in response to extracellular pH, with a peak response at 
approximately pH 6.5-7.0.  
 
To date, there are not many studies on the functions of the 3 proton 
sensing receptors. Some studies focused on the relationship between 
receptors and tumor development or the kidney.   
 
Quite a few evidence supported pH receptors enhanced tumor 
development via different pathways. It has been reported that GPR4 and 
TDAG8 were overexpressed in variety of human cancer tissues, indicating 
roles in driving or maintaining tumor formation 71, 72. In-vitro 
overexpression of GPR4 or TDAG8 in HEK293 cells were found to lead to 
a transcriptional activation to promote tumor growth via SRE- and 
CRE-driven promoters 71. And Gpr4 -/- mice showed a significantly 
reduced angiogenesis in response to VEGF and the tumor growth is 
strongly reduced in Gpr4 -/- mice 73. The tumorigenesis of melanoma cells 
was found to be significantly inhibited in OGR1 deficient mice too 74. 
TDAG8 on the surface of tumor cells was found to facilitate tumor 
development and overexpression of TDAG8 in mouse lewis lung 
carcinoma (LLC) cells enhanced tumor growth in animal models 
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depending on PKA and ERK activation 72. But some other independent 
studies reported an inconsistent result. GPR4 activation by acidosis 
inhibited tumor cell migration and metastasis in genetically engineered 
GPR4-overexpressing B16F10 melanoma cells and TRAMP-C1 prostate 
cancer cells 75. And OGR1 has been found to function as a novel 
metastasis suppressor gene for prostate cancer in an in-vivo mouse 
tumor cell migration model 76. Thus, it is quite difficult to draw a logical 
and clear conclusion from a set of contradictory data. Consequently, 
more studies are needed to further understand the roles of these 
receptors in cancer biology.   
 
In the renal system, GPR4 expression was widely observed in kidney 
cortex and kidney collecting ducts. Gpr4 -/- mice showed a decreased net 
acid renal secretion and spontaneous metabolic acidosis. The finding 
suggested that the proton sensor GPR4 regulates acid secretion in kidney 
collecting duct 77. A separate study demonstrated that chronic acidosis 
and GPR4 increase H+-K+-ATPase α subunit (HKα2) protein, implicating a 
regulatory role of GPR4 78. Previous work from our group also showed 
that OGR1 regulated the activity of two major plasma membrane proton 
transporters in proximal tubules, Na+/H+ exchanger (NHE3) and H+-ATPase 
79, indicating a role in the regulation of renal pH homeostasis.  
 
In addition to a possible involvement in tumor development and kidney 
function, several studies have demonstrated the function of proton 
activated receptors in immune processes of the lung, insulin secretion 
and sensitivity, and bone metabolism. The latest update included OGR1 
deficiency attenuated glucose-stimulated insulin secretion in vivo in a pH 
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dependent manner while acidity and OGR1 activation enhanced 
glucose-stimulated insulin secretion under physiological conditions in 
vitro 80. Ogr1 -/- mice further showed a decreased insulin secretion but 
have unusual normal glucose tolerance 80. Interestingly, Giudici et al 
reported GPR4 deficiency improved glucose tolerance and insulin 
sensitivity with comparable insulin levels but increased plasma leptin 
levels in mice 81. The effect was maintained in aged mice but not in obese 
mice. These two studies indicated OGR1 might modulate glucose 
homeostasis by boosting insulin secretion whereas GPR4 might modulate 
it by lowering insulin sensitivity 80, 81.  
 
Other research showed TDAG8 seemed to be a major regulator or 
influencer in asthma and osteoclatic bone metabolism 82-85. TDAG8 
knockout attenuated dexamethasone-induced inhibition of 
pro-inflammatory cytokine production, TNF-α, in mouse peritoneal 
macrophages and suggested that TDAG8 was partly involved in the 
steroid hormone induced anti-inflammatory function 82. Mogi et al from 
the same group further reported TDAG8 mediates the extracellular 
acidity induced suppression of TNF-α and IL-6 through the Gs/cAMP/PKA 
signaling pathway in mouse peritoneal macrophages 83. Kottyan et al 
reported 84 that the eosinophils, which are the most characteristic 
feature of asthmatic inflammation, responded to protons with improved 
cellular viability and reduced apoptosis in both human and mouse. 
Importantly, the effect was in a dose-dependent manner between pH 7.5 
and 6.0. TDAG8, identified as the chief pH receptor, was found 
overexpressed in eosinophils. More interesting, the author 
demonstrated that the acidity induced enhanced eosinophil viability was 
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dependent on cAMP production and TDAG8 84. TDAG8-deficient mice 
had attenuated airway eosinophilia and increased apoptosis in two 
asthma mouse models, which further proved the decisive role of TDAG8 
in asthmatic inflammation 84. Besides, TDAG8 may also play a role in 
bone metabolism 85. TDAG8 activation was suggested to inhibit 
osteoclastic bone resorption, which could act as a novel therapeutic 
approach for metabolic bone disease, e.g. osteoporosis or porous bone 
85.  
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1.5 Mouse models used in IBD study 
 
The available animal models of IBD can be divided into four classes 
(Table 3) 86-88: 1. Inducible colitis models in mice with a normal immune 
system. 2. Spontaneous colitis models. 3. Adoptive transfer models in 
immuno-compromised hosts. 4. Genetically engineered models including 
knockout mice and transgenic mice. All of these animal models enable us 
to better understand the mechanisms and fundamentals of 
gastrointestinal inflammatory diseases. But, among these all, an ideal 
experimental model of IBD is supposed to mimic human IBD, either UC 
or CD. And it should be easy to induce, cost effective and highly 
reproducible. Unfortunately, there is no single model available that 
completely meets all of these criteria 87-89. 
 
Trinitrobenzene sulfonic acid (TNBS) and Dextran sulfate sodium (DSS) 
induced colitis might be the most widely used animal models for IBD 
studies 86. For the induction of chronic colitis, mice receive 4 cycles of 
2-4 % DSS treatment. One cycle consists of feeding DSS in drinking water 
for 7 days followed by a period of 10 days drinking water without DSS 89, 
90. The colitis becomes evident when the mice lose weight and develop 
diarrhea. This model shares many similarities to human IBD in aetiology, 
pathology, pathogenesis and therapeutic responses. Both of the toxic 
chemicals directly damage the mucosal barrier and disrupt epithelial 
integrity. The DSS induced colitis model is a particularly suitable model 
for human IBD especially UC 89. It has been reported that morphological 
studies suggest that the administered DSS was partially phagocytized by 
macrophages in the colonic mucosa and macrophages malfunction 
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contribute to the resulting colitis 91. The chronic DSS induced colitis is 
considered to be caused by long term active lymphocytes and cytokines 
secreted by macrophages or Th1/Th2 cells 92. However, susceptibility to 
DSS highly varies with the animal species and strains 93. In mice, the 
C57BL/J6 strain of mice was found to be more susceptible to 
experimental colitis using DSS than Balb/c mouse 93. So, it is necessary to 
introduce another IBD mouse model to the study. 
 
Table 3 Overview of IBD animal models 86 
  
 
 
IL-10 is a well known suppressor of Th1 cells and macrophage activation 
and it inhibits IL-12 and TNF-alpha production 94. IL-10 also inhibits T 
cells proliferation and promotes the formation of antigen specific 
regulatory T cells 86. IL-10 -/- mice spontaneously develop chronic colitis 
and inflammation occurring in the whole intestine, which is supposed to 
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simulate CD 86, 88, 89. DRA (downregulated in adenoma, a chloride sulfate 
anion transporter causing congenital chloride diarrhea when mutated) 
transporter expression was dramatically reduced in the surface 
epithelium of colon in IL-10 knockout mice, and the attenuation of DRA 
expression in IL-10 -/- mice participate in the pathogenesis of diarrhea in 
colitis 95. The disadvantages of the IL-10 -/- mice model include that it 
takes several months to develop colitis making them unsuitable for acute 
colitis study and high throughput tests. 
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1.6 Aim of the project 
 
The motivation to initiate the project arose from the clinical clues and 
previous studies in our research group. Since local acidification has been 
observed during IBD and has been implicated in the pathogenesis and 
progression of IBD; and since OGR1 and GPR4 are expressed along the 
gastrointestinal tract, we investigated the precise role of GPR4 and 
OGR1 in this study.  
 
In preliminary experiments of the project, we found that both OGR1 and 
GPR4 mRNA are widely expressed in several mouse tissues including 
small intestine and colon. Robust expression of OGR1 mRNA was 
measured in small intestine and in colon (Wagner, unpublished data). 
More interesting, we found OGR1 and GPR4 mRNA were highly 
expressed in spleen possibly due to its abundant expression in various 
types of immune cells and leukocytes and cytokines TNF-α significantly 
upregulate OGR1 mRNA expression in Mono Mac 6 cells (Cheryl de 
Valliere, unpublished data). Taken together, considering both GPR4 and 
OGR1 are being expressed along the small and large intestine as well as 
in almost all immune cells, we hypothesized that these two proton 
sensing receptors, might participate in the pathogenesis of IBD. 
 
The hypothesis was tested by using the following IBD mouse models and 
approaches:  
 
1. dextran sulphate sodium (DSS) induced chronic colitis model 
2. Spontaneous colitis model (Gpr4 -/-/IL-10 -/- and Ogr1-/-/IL-10 -/-) 
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Abstract 
 
BACKGROUND: During active inflammation tissue and intraluminal intestinal 
pH is decreased in patients with inflammatory bowel disease (IBD). pH may 
play a role for IBD pathophysiology. Recently, proton sensing G-protein 
coupled receptors (GPCRs) were identified, including GPR4, OGR1 (GPR68), 
and TDAG8 (GPR65). We investigated whether GPR4, a prototype 
pH-sensing receptor, is involved in intestinal inflammation. 
METHODS: The impact of a deletion of GPR4 was assessed in two models of 
colitis, the chronic dextran sulphate sodium (DSS) induced model and by 
crossbreeding into IL-10 deficient background. Colitis severity was assessed 
from body weight, colonoscopy, colon length, histological score, cytokine 
mRNA expression, and myeloperoxidase (MPO) activity. In the spontaneous 
colitis model, the incidence of rectal prolapse and phenotypic and functional 
lamina propria leukocytes (LPLs) characteristics were analyzed.  
RESULTS: Gpr4 -/- mice showed less body weight loss and lower histology 
score after induction of chronic DSS colitis. In Gpr4 -/- /IL-10 -/- double 
knock-outs onset and progression of rectal prolapse were significantly delayed 
as compared to Gpr4 +/+ /IL-10 -/- mice. Similarly, histology scores and MPO 
activity were reduced in double KO mice. Gpr4 -/- /IL-10 -/- mice further had a 
lower CD4+ T-helper cell infiltration with significantly lower IFN-γ expression.  
CONCLUSION: The deletion of the GPCR GPR4 ameliorates colitis in animal 
models indicating an important role for the regulation of mucosal inflammation 
and thus providing a new link between environmental factors such as luminal 
pH and the immune system. The therapeutic inhibition of GPR4 may be 
beneficial for the treatment of IBD. 
 
Key Words: G-protein coupled receptor; pH receptors; GPR4; IBD; animal 
model.  
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Introduction 
 
 A local acidification in the gut lumen as well as in the mucosa has been 
observed during intestinal inflammation and implicated in the pathogenesis 
and progression of inflammatory bowel disease (IBD). Fallingborg et al. 
reported that intraluminal colonic pH values in patients with active ulcerative 
colitis (UC) were significantly lower than normal subjects (lowest values 2.3, 
2.9, and 3.4) in the proximal parts of the colon (1). Similarly, Raimundo et al. 
reported luminal pH as low as 4.7 in the proximal colon in patients with both 
active and inactive UC (2). Nugent and coworkers also reported a decrease of 
colonic luminal pH values to less than 5.5 in two of six patients with active UC 
(3). Also in patients with active Crohn’s disease (CD) three out of four CD 
patients investigated had decreased pH value in the proximal colon (pH 5.3) 
and distal colon (pH 5.3) as compared to normal controls (pH 6.8) (3). While 
there is still some discussion about the range of the intestinal luminal pH in IBD 
patients (4),(5), it is widely accepted that inflammation is accompanied by 
tissue acidosis associated with glucose uptake due to hypoxia and excessive 
production and insufficient elimination of glycolytic metabolites. This indicates 
that during active IBD luminal and tissue pH is decreased. The 
(patho)physiological impact of these observations, however, has remained 
incompletely understood to date. 
 G protein-coupled receptors play an important role in regulating intestinal 
functions and have been implicated in the development and course of 
inflammatory bowel disease (6).  Only recently, we found that the GPCR 
OGR1 plays a role in inflammatory bowel disease and that genetic deletion of 
OGR1 ameliorates the development of inflammatory bowel disease in the IL10 
deficient IBD mouse model (7). OGR1 (ovarian cancer G protein coupled 
receptor 1, OGR1, GPR68) belongs to a novel family of proton-activated G 
protein-coupled receptors including also GPR4 and the T-cell death associated 
gene 8 (TDAG8, GPR65) (8-10). Accumulating evidence indicates that all of 
these three GPCRs (GPR4, OGR1 and TDAG8) are activated by protons upon 
a decrease of pH in the range of pH 7.6 (inactive) to pH 6.8 (fully activated) 
and may play a crucial role in pH homeostasis (8, 10).  
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 GPR4 activation is transduced via the Gas pathway, followed by 
intracellular cAMP accumulation (8, 10). Half-maximal activation of cAMP 
formation by GPR4 expressed in HEK293 occurred at pH 7.55 (10). Limited 
studies exist on the relationship between GPR4 and tumor development or 
regulation of metabolic acidosis in the kidney (11-17).  The function of 
proton-activated receptors has been linked to inflammation(18) but the role of 
GPR4 in inflammatory disease has remained unknown. GPR4 mRNA was 
found to be widely expressed in a variety of mouse tissues including small 
intestine, colon, spleen, and localized to among other cell types to endothelial 
cells throughout the body. Considering GPR4 being expressed along the small 
and large intestine, we hypothesized that this proton-activated receptor might 
be involved in sensing local pH changes and may participate in the 
pathophysiology of IBD. Since local acidification of pH has been observed 
during IBD and the interaction between immune system and pH-sensing 
receptors is poorly understood, we postulate that GPR4 might be a player in 
mucosal inflammation during IBD. 
 Therefore, we examined the role of GPR4 in two models of colitis in vivo, 
the dextran sulphate sodium (DSS) induced chronic colitis model and the 
spontaneous colitis model in IL-10 deficient animals. Collectively, these data 
demonstrate that deletion of GPR4 is associated with ameliorated colitis and 
thus pH sensing plays an important role in the pathophysiology of IBD. 
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Methods and Materials 
 
Human colonic biopsies 
 Biopsies of human colon were collected from patients during colonoscopy 
performed at the Division of Gastroenterology and Hepatology, University 
Hospital Zurich (Switzerland). CD patients (8 with severe, 7 with moderate 
inflammation and 14 in remission) and UC patients (5 with severe and 3 with 
moderate inflammation) underwent colonoscopy for assessment of 
inflammation and disease severity. Biopsies from patients with colitis were 
taken endoscopically from inflamed areas. The normal control tissues (17 
controls) were from subjects undergoing colonoscopy as a screening 
procedure for colo-rectal cancer. The protocol for the study was approved by 
the ethics committee, University Hospital Zurich.  
 
 
Genomic DNA extraction and genotyping  
 DNA extraction was done according to standard NaOH digestion. The PCR 
reactions used for GPR4 genotyping were set up with following 
oligonucleotides: 5’-atgggatcggccattgaacaa-3’ (TS426), 
5’-tcatcctgatcgacaagacc-3’ (TS427), 5’- gctgccatgtggactctcga-3’ (TS428), 
5’-caggaaggcgatgctgatat-3’ (TS429). TS426-TS427 is specific for neo (479 
bps), and TS428-TS429 is specific for the GPR4 allele (302 bps).  
 
Induction of chronic colitis with DSS 
 Gpr4 -/- mice (BALB/c and C57BL/6 background) were provided by 
Thomas Suply and Klaus Seuwen, Novartis, Basel. All transgenic strains were 
bred in the standard animal facility of the Institute of Physiology, University of 
Zurich. All animal experiments were performed in the Zurich Integrative Rodent 
Physiology (ZIRP) core facility according to the guidelines of the Swiss animal 
welfare law and approved by the Cantonal Veterinary Office Zurich, 
Switzerland.  
Three experiments (2 experiments on a BALB/c and one on a C57/BL6 
background) were performed with DSS (MP Biomedicals, LLC, Solon, OH, 
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USA) induced chronic colitis. Female mice at the age of 10-13 weeks and a 
body weight around 20g were used in the experiment. Gpr4 -/- mice and 
wild-type mice received 3% DSS in drinking water for 7 days followed by 10 
days recovery on water. Cycles were repeated three times. After the last cycle 
all animals were allowed to recover for 5 weeks and subsequently sacrificed 
for sample collection. Mice on water served as controls throughout the 
experiments. 
 Histological analysis was performed as described previously (19-21). The 
sections were stained with hematoxylin and eosin (H&E) and scored twice in a 
blinded fashion. 
 
Gpr4 -/- /IL-10 -/- mice 
 Gpr4 -/- mice (C57BL/6) were bred to IL-10 -/- mice (C57BL/6) with the goal 
to generate Gpr4 -/- /IL-10 -/- mice. Mice were routinely screened using PCR 
reactions for: IL-10 forward 5’-GTGGGTGCAGTTATTGTCTTCCCG-3’ 
(oIMR0086), reverse 5’-GCCTTCAGTATA Grp4 forward  AAAGGGGGACC-3’ 
(oIMR0087), Grp4 reverse 5’-CCTGCGTGCAATCCATCTTG-3’ (oIMR0088). 
In experiments WT littermates were used as controls. The onset and 
development of inflammatory markers, colitis and rectal prolapses was 
monitored over 200 days and data was analyzed using Kaplan-Meier analysis 
(log rank Mantel-Cox test). For the evaluation by histology, flow cytometry, and 
for the determination of cytokine (mRNA) expression profiles, some mice were 
sacrificed by cervical dislocation at 80 days of age. 
 
Assessment of colonoscopy score in mice 
 Mucosal damage was assessed by the murine endoscopic index of colitis 
severity (MEICS) as described previously (20-23). Animals were 
anaesthetized intraperitoneally with a mixture of 90-120 mg of ketamine 
(Narketan 10%, Vétoquinol AG, Bern, Switzerland) and 8 mg of xylazine 
(Rompun 2%, Bayer, Zurich, Switzerland) per kg body weight and examined 
by colonoscopy (Karl Storz Tele Pack Pal 20043020, Karl Storz Endoskope, 
Tuttlingen, Germany).  
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Myeloperoxidase (MPO) activity assay 
 MPO activity was calculated by photoabsorbance, as previously described 
(20-21). Briefly, colon tissues were homogenized in 50 mM PBS (pH 6.0) with 
0.5% hexadecyltrimethylammonium bromide (H-5882, Sigma). After 
performing three cycles of freeze-and-thaw, 20 µl of the homogenates 
supernatant were mixed with 280 µl of 0.02% dianisidine (D-3252, Sigma) 
solution. After 20 min incubation at room temperature, absorbance was 
measured at 460 nm. Protein concentration of the colon tissue supernatant 
was determined by Bradford protein assay (Bio-Rad). MPO activity was 
calculated as mean absorbance/incubation time/protein concentration. 
 
RNA extraction and quantitative Real-Time RT-PCR 
 mRNA was extracted from colon and mesenteric lymph nodes tissue using 
the Qiagen RNeasy Mini Kit at a Qiacube workstation (Qiagen; Hilden, 
Germany) according to the manufacturer’s instructions (20-21). cDNA was 
prepared from adjusted RNA samples (2µg/20µl reaction) using the TaqMan 
High Capacity Reverse Transcriptase Reagent Kit (Applied Biosystems; 
Forster City, CA, USA). Thermocycling conditions for reverse transcription 
were set at 25 °C for 10 minutes, 37 °C for 120 minutes, 85 °C for 5 seconds 
(TGradient thermocycler, Biomera; Goettingen, Germany).   
 Quantitative RT-PCR Taqman assays (7900 Fast Real Time PCR system, 
Applied Biosystems; Forster City, CA, USA) were performed under the 
following cycling conditions: 20 seconds at 95 °C, then 45 cycles of 95 °C for 3 
seconds and 60 °C for 30 seconds with the TaqMan Fast Universal Mastermix. 
TaqMan assay probes for GPR4, TDAG8, OGR1, iNOS, IL-10, TNF-α, IFN-γ, 
IL-6, IL-18, MCP-1 (Life Technologies/ABI; Forster City, CA, USA) were used 
(Supplementary Table 1). RNA samples from individual animals were run in 
triplicates including a negative control (without cDNA). The comparative ∆Ct 
method was applied to determine the quantity of the cytokines relative to the 
endogenous control GAPDH (mouse GAPDH, Mm03302249_g1, 
Reporter=VIC and Quencher=MGB) and a reference sample. The relative 
quantification value was expressed and shown as 2−∆Ct. 
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Preparation of lamina propria lymphocytes (LPLs) 
 Lamina propria lymphocytes (LPLs) were isolated from Gpr4 -/- /IL-10 -/-, 
Gpr4 +/+ /IL-10 -/- and Gpr4 +/+ /IL-10 +/+  mice at 80 days of age following a 
slightly modified protocol by Weigmann (24). Briefly, the dissected colon was 
washed with Ca+- and Mg+-free PBS. The tissue was cut and incubated in 
medium containing 20 mM EDTA (Sigma-Aldrich) for 30 min at 37° C under 
shaking. LPLs were isolated from the lamina propria by enzymatic digestion (in 
DMEME medium containing 300 U/mL collagenase type I, 2 mg/mL 
Hyaluronidase, 0.3 mg/ml DNase and 5 mM CaCl2.2H2O) for 15 min at 37 °C 
under shaking. The LPLs were purified by discontinuous Ficoll density-gradient 
centrifugation. 
 
Flow Cytometric Analysis (FACS) 
 Single cell suspensions from lamina propria (LP) of mice were prepared as 
described above and stained for analysis by flow cytometry using PBS 
containing 4% FCS and 2.5 mM EDTA. At least 0.5×106 LP cells/well were 
stained at 4°C in the dark with the following fluorochrome-labeled monoclonal 
antibodies (all from BD): α-CD3, α-CD4, α-CD8, α-CD25, α-CD45.2, and 
α-CD161 (NK1.1). Viable cells were acquired on a FACS Canto II (BD 
Biosciences) and analyzed using FlowJo software (TriStar Inc). 
 
Statistical Analysis 
 Statistical analyses were performed using GraphPad Prism 5 (Version 
5.04, GraphPad Software Inc, San Diego, CA, US) and SPSS (8.0 for 
Windows; SPSS Inc, Chicago, IL, US). Groups of data were compared 
between genotypes using nonparametric Mann-Whitney U-test or 
Kruskal-Wallis one-way ANOVA followed by Dunn’s multiple-comparison test. 
All data were expressed as the means ± SEM. Probabilities (p, two tailed) of p 
< 0.05 were considered statistically significant. Body weight comparison was 
performed using “General Linear Model, repeated measures”, and the full 
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factorial model with type III sum of squares method(25). The “General Linear 
Model, repeated measures” integrated both “individual deviation of daily body 
weight” and “difference in genotype groups” into the analysis to avoid systemic 
bias (25).  
 For prolapse ratio comparison studies, statistical differences between 
genotypes were calculated by chi-square test with Fisher’s exact test (exact 
significance, two sided) and risk estimate test from contingency table. The 
prolapse survival analysis was performed using Kaplan-Meier prolapse-free 
survival analysis (log rank Mantel-Cox test) and estimated median 
prolapse-free survival time.  
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Results 
 
GPR4 expression in the colon of normal subjects and IBD patients 
Semiquantitative RT-qPCR confirmed mRNA expression of GPR4 in 
normal colon and IBD patients’ colon. mRNA expression of GPR4 was 
significantly higher in the colon of patients with active UC (5.3-fold, P< .05 *) 
and in CD patients in remission (5.8-fold, P< .001 ***) (Figure 1.A). GPR4 
expression in patients with CD was increased 2.7-fold and 2.5 fold (severe and 
moderate groups). In patients with active UC, a 3.1-fold (severe group) 
increase in the level of GPR4 expression was observed.  
In mice, DSS-induced chronic colitis caused no upregulation of mRNA 
expression for the two other members of the pH receptor family, TDAG8 and 
OGR1, in colonic tissue, from both Gpr4 +/+ and Gpr4 -/- mice (Figure 1.B). This 
indicates that these two pH receptors were not upregulated on mRNA level to 
compensate for the lack of GPR4 in vivo. Moreover, during acute colitis (7 
days DSS) wildtype mice displayed increased TDAG8 expression, but no 
increase in GPR4 or OGR1 expression in the colon (Figure 1.C) This 
observation likely reflects immune cell infiltration, where TDAG8 is highly 
expressed. 
 
DSS induced chronic colitis is attenuated in mice lacking Gpr4 
Since GPR4 is expressed in human inflamed colonic tissue and other 
proton-activated receptors from the same family have been linked to 
inflammatory diseases, we tested the impact of genetic deletion of GPR4. 
Compared with Gpr4 +/+ mice, Gpr4 -/- mice showed less reduction in body 
weight upon DSS treatment (Fig. 2). A total of 22 DSS treated Gpr4 +/+ (16 
BALB and 6 C57BL/6) mice and 18 DSS treated Gpr4 -/- (11 BALB and 7 
C57BL/6) mice in 3 independent experiments were compared with 5 Gpr4 +/+ 
and 6 Gpr4 -/- control mice (C57BL/6) receiving normal water. From day 62 to 
day 83 (22 days after the fourth DSS cycle) Gpr4 -/- mice had lost clearly less 
body weight and showed an enhanced ability to regain weight (F=2.980, 
P< .05 *, Figure 2A). All 3 independent experiments showed qualitatively 
similar results: Gpr4 -/- mice suffered less body weight loss, indicating a 
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protective effect of GPR4 deficiency (P< .05 for BALB (exp 1), P< .05 * for 
BALB (exp 2) and P< .01 ** for C57BL/6 background) independent of the 
genetic background.  
 
Histological analysis provided evidence (Figure 2B) that Gpr4 -/- +DSS 
mice had attenuated colonic inflammation. The total histological score for DSS 
treated Gpr4 -/- mice (2.3 ± 0.38) was significantly lower as compared to DSS 
treated Gpr4 +/+ mice (4.9 ± 0.81) (P< .001, Supplementary Figure 1). Water 
control and Gpr4-/- mice showed almost no signs of inflammation. Gpr4 -/- mice 
had lower scores for both epithelial injury and leukocyte infiltration (P< .001 for 
both) (Figure 2B and 2C). Again, all 3 experiments showed consistent results 
independent of genetic background.  
In contrast DSS treated Gpr4 -/- had slightly shorter colon lengths and a 
higher endoscopic MEICS score (P< .05, Supplementary Figure 2A and 2B). 
GPR4 deficiency did not change MPO activity and spleen weight upon DSS 
(Supplementary Figure 2C and 2D). Cytokine expression profiling for iNOS, 
IL-10, TNF-α, IFN-γ, IL-6, and MCP-1 was not different in colon and 
mesenteric lymph node tissues between Gpr4 +/+ and Gpr4 -/- mice upon DSS 
induced colitis (Figure 3 and Supplementary Figure 2E).  
 
Spontaneous colitis is attenuated in Gpr4/IL-10 double knock out 
animals 
Next, we assessed the impact of GPR4 in a spontaneous colitis model. 
The occurrence of rectal prolapse as a sign of spontaneous colitis in IL-10 -/- 
mice was monitored for 200 days. In comparison with Gpr4 +/+ /IL-10 -/- mice, 
both female and male Gpr4 -/- /IL-10 -/- mice, had a lower rectal prolapse 
incidence (female: 6.9%, n = 29 vs. 66.7%, n = 12, P< .001 , odds ratios of 
Gpr4 -/-/Gpr4 +/+ = 0.037 (95% CL 0.006-0.241); male: 24.4%, n=41 vs. 52.0%, 
n=25, P= .033, odds ratios = 0.298 (95% CL 0.103-0.859); chi-square test with 
Fisher’s exact test/two sided). All mice were maintained in the same OHB 
room and all experiments were carried out during the same time period. No 
prolapses were observed in any control Gpr4 +/+ /IL-10 +/+ mice in the breeding 
colonies for 200 days (n > 100 for each gender). 
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Kaplan-Meier prolapse-free survival analysis showed a significantly 
delayed onset of rectal prolapse in Gpr4 -/- /IL-10 -/- mice as compared to Gpr4 
+/+ /IL-10 -/- mice (estimated median prolapse-free survival time, female: >200 
days vs. 123 days, P< .001; male: >200 days vs. 161 days, P= .007, log rank 
(Mantel-Cox) test, Figure 4A and Supplementary Figure 3A).  
Figure 4B (and Supplementary Figure 3B) illustrate the level of granulocyte 
infiltration as measured by MPO activity in colon tissue of mice at 80 days of 
age. This age was chosen as none of the mice had developed a prolapse at 
this age. In Gpr4 -/- /IL-10 -/- male mice, MPO activity was significantly lower 
than that in Gpr4 +/+ /IL-10 -/- male mice (0.013±0.068 vs. 0.53±0.101, P< .05). 
A similar trend was seen in female Gpr4 -/- /IL-10 -/- animals (Figure 4B). 
Compared with control Gpr4 +/+ /IL-10 -/- mice, Gpr4 -/- /IL-10 -/- mice were not 
different with respect to colon length and relative spleen weight (except for 
Gpr4 -/- /IL-10 -/- female mice, P< .05, Figure 4C and D and Supplementary 
Figure 3C and 3D). 
 
Histological analysis of murine colons from 80 days old mice showed that 
colons from male (histological score of 1.6±0.91) and female (1.6±0.93) Gpr4 
+/+ /IL-10 +/+ mice were morphologically normal. Gpr4 -/- /IL-10 -/- male (2.3±0.68) 
and female (2.6±1.69) mice displayed significantly less mucosal injury and 
infiltration as compared to Gpr4 +/+ /IL-10 -/- male (6.3±0.45) and female 
(6.5±1.12) mice (P< .05 for both), consistent with the prolapse ratio and 
prolapse-free survival analysis. (Figure 5 and Supplementary Figure 4). 
 
 
Reduction of mucosal CD4+ T helper cell infiltrate upon Gpr4 deficiency 
Spontaneous colitis in IL-10 deficient mice is mediated by Th1 and Th17 
cell infiltration (26-27). In order to identify cellular players underlying the 
reduced colitis in GRP4-/- mice we subsequently measured cellular infiltrates in 
the lamina propria by flow cytometry. As shown in Figure 6 and Supplementary 
Figure 5, the percentage, the CD8 to CD4 ratios, as well as CD4+ T cell 
numbers were significantly higher in Gpr4 +/+ /IL-10 -/- as compared to Gpr4 +/+ 
/IL-10 +/+ controls (P< .01, P< .001  and P< .001). Gpr4 +/+ /IL-10 -/- mice had 
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significantly higher counts of CD4+ cells, but not CD8+ in the lamina propria. 
No changes of Treg, NK cells, CD45+ total immune cells, non-B & non-T cells, 
macrophages and monocytes/neutrophils in LPLs composition were observed 
among the three groups (Supplementary Table 2).  
 
We further characterized cytokine mRNA expression in colon tissue and 
mesenteric lymph nodes using age-matched female (Figure 7 and 
Supplementary Figure 6) and male (Supplementary Figure 7) mice at 80 days 
of age. As shown in Figure 7, IFN-γ expression was significantly lower in Gpr4 
-/- /IL-10 -/- mice (P< .05), which reconfirmed reduced Th1 -cell infiltrate in mice 
lacking GPR4. Furthermore, Gpr4 -/- /IL-10 -/- mice showed lower mRNA 
expression for iNOS, IL-6, MCP-1, CXCL2, CXCL1, SELE, VCAM1 as 
compared to Gpr4 +/+ /IL-10 -/- mice (Figure 7). 
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Discussion 
 
This is the first study on the (patho-)physiological function of the 
proton-activated G-protein coupled receptor GPR4 in the intestine and its 
impact on intestinal inflammation. We demonstrate that GPR4 deletion 
protects against experimental colitis in both DSS-induced chronic colitis and 
the IL-10-induced colitis.  
 
According to the National Center for Biotechnology Information (NCBI) 
Gene Expression Omnibus (GEO) profile and Gene database 
(http://www.ncbi.nlm.nih.gov/sites/geo) and the BioGPS database of The 
Scripps Research Institute (http://biogps.org)) the human small intestine and 
colon express GRP4 at moderate levels. Here, we demonstrate that GPR4 
mRNA is strongly up-regulated in the colons of IBD patients (Figure 1A and 
GEO Profile database ID: 12504653 and 4234799). In the chronic DSS colitis 
model (26-29), Gpr4 -/- mice lost less body weight and had lower histology 
scores compared to WT littermates indicating less severe inflammation. In the 
spontaneous IL-10-mediated colitis model (30-32) lack of GPR4 significantly 
delayed onset and progression of rectal prolapses which could explain the 
protective role of Gpr4 deficiency in experimental colitis. As IL-10 is a 
well-known anti-inflammatory cytokine and suppressor for Th1 cells and 
macrophages (33), IL-10 knockout mice are thought to have a Th1-cell driven 
disease (26-27). Consistent with less Th1 cell infiltrate in Gpr4 -/- /IL-10 -/- mice 
a significantly lower IFN-γ expression was found. Further, LPL-infiltration 
measured by flow cytometry demonstrated that GPR4 knockout partially 
reduced infiltration of CD4+ T cells. Finally, the anti-inflammatory effect of 
GPR4 deficiency seemed not to be mediated by elevated Treg levels as no 
significant changes in Treg numbers were observed between groups.  
 
Therefore, in turn, activation of GPR4 is likely to exacerbate intestinal 
inflammation and trigger inflammatory responses via the Gs-cAMP-Th1-IFN-γ  
pathway. IFN-γ aggravates inflammation by increasing iNOS expression, 
activating macrophages and NK cells and inducing apoptosis (34-35). The 
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excessive production of glycolytic metabolites in inflamed tissue causes the 
accumulation of protons, which may further activate GPR4, forming a positive 
feedback loop which may lead to a vicious cycle. Thus blockade of GPR4 may 
be a promising new target for IBD treatment. 
 
Recent data published on Gpr4 -/- mice support the negative role of GPR4 
activation during inflammation. Gpr4 -/- mice showed an impaired response to 
VEGF-driven angiogenesis in a growth factor implant model and had less 
tumor growth (12). Moreover, both GPR4 knockout and GPR4 inhibition by 
specific siRNAs resulted in decreased VEGFR2 (VEGF receptor 2, the main 
signaling receptor for VEGF on endothelial cells) levels, which might be one of 
the reasons for a reduced angiogenic response to VEGF (12). In addition 
GPR4 may be involved in inflammation, autoimmunity and allergy. In vitro 
stimulation of GPR4 caused upreglation of many transcripts involved in 
inflammatory processes(36). Reduced immune responses and attenuated 
airway hyper-responsiveness were observed in GPR4 deficient mice following 
ovalbumin exposure (37). This was accompanied by a reduction in the number 
of eosinophils in broncho-alveolar lavage fluid (38). In the cigarette 
smoke-induced COPD mouse model, Gpr4 -/- mice had accelerated elimination 
of airway inflammation and enhanced neutrophil clearance (39).In patients with 
systemic Sclerosis, expression of GPR4 correlates with the severity of lung 
disease (40). 
 
Yang et al. found evidence that acidosis/GPR4 signaling regulates 
endothelial cell adhesion mainly through the Gs/cAMP/Epac pathway (41). The 
activation of GPR4 by acidosis up-regulated the expression of multiple 
adhesion molecules such as SELE, VCAM-1 and ICAM-1 in vitro and 
increased the adhesiveness of human umbilical vein endothelial cells 
(HUVECs) expressing endogenous GPR4. These adhesion molecules are 
involved in the binding of leukocytes (41). In our studies Gpr4 -/- /IL-10 -/- mice 
expressed lower mRNA levels of iNOS, TNF-α, IFN-γ, IL-6, MCP-1, CXCL2, 
CXCL1, SELE and VCAM-1 which at least in part is in agreement with the 
mentioned in vitro observations. A regulation of the NF-κB pathway by 
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Gpr4-dependent signalling has been postulated (36) further supporting our 
findings.  
 
In summary, our results demonstrate that Gpr4 -/- deficiency protects from 
experimental colitis indicating an important pathophysiological role for the 
proton-activated receptor during the pathogenesis of mucosal inflammation. 
GPR4 may become a promising novel target for pharmacological IBD therapy. 
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Figure legends 
 
Figure 1  
GPR4 mRNA detection in colonic tissue from humans and mice.  
(A) GPR4 mRNA was detected in colonic biopsies from controls (normal 
subjects), and patients with ulcerative colitis (UC), or Crohn’s disease (CD) by 
real-time RT-PCR Taqman assays. A minimum of 5 patients per group was 
tested for quantification. (B) GPR4 mRNA detection in colonic tissues from 
wildtype mice or Gpr4 -/- mice with water or DSS induced chronic colitis. (C) 
GPR4 mRNA detection in colonic tissues from wildtype mice or wildtype mice 
with acute DSS induced colitis (7 days). The relative amount of GPR4 mRNA 
was determined via normalization across all samples to the housekeeping 
control gene GAPDH. Groups of data were compared between control group 
and different individual group using the non-parametric Kruskal-Wallis one-way 
ANOVA followed by Dunn’s multiple-comparison test. For quantification, values 
are mean ± SEM; n ≥ 5 per group; P< .01 **, P < .001 ***. 
 
 
Figure 2  
Body weight loss analysis and histological assessment of colonic 
inflammation. 
(A) Gpr4 -/- mice, compared with Gpr4 +/+ mice, showed less relative body 
weight loss during DSS-induced chronic colitis. After 4 cycles of DSS 
treatment (last 22 days), Gpr4 -/- mice exhibited clearly reduced gain of body 
weight (F=2.980, P< .05 *) than Gpr4 +/+ mice. The body weight changes are 
expressed as relative change of body weight in % relative to day 0. Histology 
scores were analyzed to assess the epithelial damage (B) and leukocyte 
infiltration (C) indicating less severe inflammation in Gpr4 -/- mice with DSS. 
The right panel shows a representative histological section from wild-type or 
Gpr4 -/- mice treated with DSS Data are representative of 3 independent 
experiments each with 6-8 female mice/ group. 
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Figure 3  
Assessment of the colitis severity during DSS induced chronic colitis. 
The mRNA expression levels of iNOS, IL-10, TNF-α, IFN-γ, IL-6, and MCP-1 in 
colon from Gpr4 -/- mice and Gpr4 +/+ mice with or without administration of 
DSS were not changed between genotypes for the same treatment. For 
quantification, values are mean ± SEM; n ≥ 5 per group; P < .05 *, P < .01 **, P 
< .001 ***. Data are representative of 3 independent experiments. 
 
 
 
Figure 4  
Development of IBD and progression to prolaps were reduced by the 
deletion of GPR4 from IL10 deficient mice.  
(A) Kaplan-Meier prolapse-free survival curve showed delayed onset and 
progression of prolapses in female Gpr4 -/- /IL-10 -/- mice relative to female 
Gpr4 +/+ /IL-10 -/- mice (estimated median prolapse-free survival time, >200 
days vs. 123 days, P= .000 ***, log rank (Mantel-Cox) test). Black dotted lines, 
Gpr4 -/- /IL-10 -/- mice (6.9% prolapses, n=29, female); black solid line, Gpr4 +/+ 
/IL-10 -/- mice (66.7% prolapses, n=12, female); grey dotted lines, Gpr4 +/+ 
/IL-10 +/+ mice (0% prolapses, n=31, female). No rectal prolapse was detected 
in the Gpr4 +/+ /IL-10 +/+ mice in these breeding colonies for 200 days (> 100 
mice). Comparison of MPO activity in colon tissue (B), colon length (C), and 
relative spleen weight (D) showed attenuated colitis in female Gpr4 -/- /IL-10 -/- 
mice (not significant but relative spleen weight, P< .01 **, Kruskal-Wallis 
one-way ANOVA followed by Dunn’s multiple-comparison test). 
 
 
Figure 5  
Less histological damage in Gpr4 -/- /IL-10 -/- female mice.  
(A) The total histology scores of distal colon of female Gpr4 -/- /IL-10 -/-, Gpr4 +/+ 
/IL-10 -/- and Gpr4 +/+ /IL-10 +/+ mice at 80 days of age are shown, indicating 
reduced inflammation in Gpr4 -/- /IL-10 -/- mice (P< .05, Gpr4 -/- /IL-10 -/- 
compared to Gpr4 +/+ /IL-10 -/-).  (B) H&E stained sections showed the 
significant difference in the damage of epithelial integrity and intensity of the 
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leukocyte infiltration into inflamed sites. The total histology scores are 
representative for overall histology scores of distal colon (epithelial injury plus 
leukocyte infiltration). Data are presented as mean ± SEM; n ≥ 5 per group; P 
< .05 *, P < .01 **, P < .001 ***. 
 
 
Figure 6  
Suppression of IFN-γ-producing CD4+ T helper cells in Gpr4 -/- /IL-10 -/- 
mice.  
LPLs were isolated from the colon of female Gpr4 -/- /IL-10 -/-, Gpr4 +/+ /IL-10 -/- 
and Gpr4 +/+ /IL-10 +/+ mice, stained to identify subpopulations and analyzed by 
FACS. LPLs profiles from FACS analysis demonstrated that ablation of GPR4 
suppressed accumulation of CD4+ (T helper) cells, mainly Th1 cells, but not 
CD8+ (T cytotoxic) cells: quantification of CD4+ T cells, percentage of CD4+ 
cells in CD3+ T cells, comparison of CD4+/CD8+ ratio, quantification of CD8+ T 
cells, and percentage of CD8+ cells in CD3+ T cells. The difference between 
Gpr4 -/- /IL-10 -/- and Gpr4 +/+ /IL-10 -/- did not reach statistical significance. 
Representative FACS results from more than 5 qualitatively similar 
experiments are shown; isolated LPLs from 3 female mice were pooled in each 
group. Data are presented as mean ± SEM; P < .05 *, P < .01 **, P< .001 ***. 
 
 
Figure 7  
Analysis of mRNA expression profiles of cytokines in colon from Gpr4 -/- 
/IL-10 -/-, Gpr4 +/+ /IL-10 -/- and Gpr4 +/+ /IL-10 +/+ mice.   
The mRNA expression profiles of iNOS, IFN-γ, IL-6, MCP-1, CXCL1, and 
CXCL1 were analyzed by semi-quantitative RT-qPCR in colon tissue from of 
all three female strains (Gpr4 -/- /IL-10 -/-, Gpr4 +/+ /IL-10 -/- and Gpr4 +/+ /IL-10 +/+ 
mice). Th1 associated IFN-γ expression was significantly lower in colon of 
female Gpr4 -/- /IL-10 -/- mice compared with female Gpr4 +/+ /IL-10 -/- mice 
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(P< .05 *, Kruskal-Wallis one-way ANOVA followed by Dunn’s 
multiple-comparison test). Data are presented as relative expression 
normalized to the house-keeping gene GAPDH, n = 6-9 mice per group. Data 
are presented as mean ± SEM; P < .05 *, P < .01 **, P< .001 ***.  
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Supplement Table 1 List of TaqMan assay probes
Gene 
Symbol Gene Name Assay ID
GAPDH Mouse glyceraldehyde-3-phosphate dehydrogenase Mm03302249_g1
GPR4 Mouse G protein coupled receptor 4 Mm00558777_s1
TDAG8 Mouse TDAG8 (G protein coupled receptor 65) Mm00433695_m1
OGR1 Mouse OGR1 (G protein coupled  receptor 68) Mm00558545_s1
iNOS Mouse nitric oxide synthase 2 Mm01309893_m1
IL-10 Mouse Interleukin 10 Mm00439615_g1
TNF- Mouse tumor necrosis factor alpha Mm99999068_m1
IFN- Mouse interferon gamma Mm00801778_m1
IL-6 Mouse Interleukin 6 Mm00446190_m1
IL-18 Mouse Interleukin 18 Mm00434225_m1
MCP-1 Mouse chemokine (C-C motif) ligand 2 Mm00441242_m1
CXCL2 Mouse chemokine (C-X-C motif) ligand 2 Mm00436450_m1
CCL20 Mouse chemokine (C-C motif) ligand 20 Mm01268754_m1
CXCL1 Mouse chemokine (C-X-C motif) ligand 1 Mm04207460_m1
SELE Mouse selectin, endothelial cell Mm00441278_m1
VCAM1 Mouse vascular cell adhesion molecule 1 Mm01320970_m1
COX-2 Mouse prostaglandin-endoperoxide synthase 2 Mm00478374_m1
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Supplement Table 2 – FACS summary
 Gpr4 +/+ /IL-10 +/+ Gpr4 +/+ /IL-10 -/- Gpr4 -/- /IL-10 -/-
Total CD3+ T cells in LPL 77700 ± 21030 366600 ± 168000 125700 ± 64930 
CD3% in CD45+ 24.2 ± 3.7 29.0 ± 2.7 27.8 ± 3.0
Total CD45+ T cells in LPL 311700 ± 67800 1293000 ± 545600 488200 ± 272800 
CD45 % in viable single LPL 63.8 ± 8.4 83.7 ± 6.7 71.7 ± 12.2
Total Treg cells in LPL 7249 ± 1325 22140 ± 3446 16300 ± 9012 
Treg % in CD4+ 35.9 ± 2.9 21.4 ± 2.6 24.3 ± 2.9 
Supplementary Table 2 
Analysis of T Cell Subsets in Gpr4+/+ /IL-10+/+, Gpr4+/+ /IL-10 -/- and Gpr4 -/-
/IL-10 -/- mice. 
Female mice were sacrificed at 80~110 days old and the tissues pooled from 3 
mice in each group. LPLs were stained with labeled antibodies and analyzed 
by flow cytometry as described in methods. T cell subsets were stained with 
APC conjugated anti-CD45.2, FITC conjugated anti-CD3, PE conjugated 
anti-CD25, PB-Alexa 405 conjugated anti-CD4 and APC-Cy7 conjugated 
anti-CD8 and analyzed by FACS. There were no statistics significance in Total 
CD3+ T cells in LPLs, CD3% in CD45+, total CD45+ T cells in LPLs , CD45 % in 
viable single LPLs, total Treg cells in LPLs, Treg % in CD4+ between all three 
groups. Representative results of flow cytometric analysis of more than 5 
independent experiments are shown. Data are presented as mean ± SEM.
Supplementary Figure 1
The total histology scores showed attenuated inflammation in GPR4 KO 
mice upon DSS colitis.
The total histology scores of distal colon for Gpr4 +/+ +H2O, Gpr4 -/- +H2O, Gpr4 
+/+ +DSS and Gpr4 -/- +DSS mice are shown. The total histology scores are 
representative for overall histology scores of distal colon (epithelial injury plus 
leukocytes infiltration). Data are presented as mean ± SEM; n 	
	p
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<0.05 *, p <0.01 **, p <0.001 ***. 
 
 
Supplementary Figure 2  
Assessment of the colitis severity during DSS induced chronic colitis. 
Colon length, colonoscopy scores, relative spleen weight, myeloperoxidase 
(MPO) activity and mRNA expression profiles of cytokines were assessed in 
Gpr4+/+ and Gpr4-/- mice treated with water or DSS, respectively. Colon length 
(A) and colonoscopy scores (B) showed aggravated inflammation in Gpr4 -/- 
mice upon DSS colitis. Gpr4+/+ and Gpr4 -/- mice showed similar relative spleen 
weight (spleen weight (mg) x 100 / body weight (g)) (C) and MPO activity in 
colonic tissue (D) upon DSS treatment. (E) The mRNA expression levels of 
iNOS, IL-10, TNF-α, IFN-γ, IL-6, IL-18 and MCP-1 in mesenteric lymph nodes 
from Gpr4 -/- mice and Gpr4 +/+ mice with or without administration of DSS were 
not changed.. For quantification, values are mean ± SEM; n ≥ 5 per group; P 
< .05 *, P < .01 **, P < .001 ***. Data are representative of 3 independent 
experiments. 
 
Supplementary Figure 3  
Development of IBD and progression of prolapse differ between Gpr4 -/- 
/IL-10 -/- and Gpr4 +/+ /IL-10 -/- male mice.  
(A) Kaplan-Meier prolapse-free survival curve showed delayed onset and 
progression of prolapse in male Gpr4 -/- /IL-10 -/- mice relative to male Gpr4 +/+ 
/IL-10 -/- mice (estimated median prolapse-free survival time, >200 days vs. 
161 days, ** p=0.007, log rank (Mantel-Cox) test). Black dotted lines, Gpr4 -/- 
/IL-10 -/- mice (24.4% prolapses, n=41, male); black solid line, Gpr4 +/+ /IL-10 -/- 
mice (52.0% prolapses, n=25, male); grey dotted lines, Gpr4 +/+ /IL-10 +/+ mice 
(0% prolapses, n=26, male). Comparison of MPO activity in colon tissue (B), 
colon length (C) and relative spleen weight (D) showed attenuated colitis in 
male Gpr4 -/- /IL-10 -/- mice (not significant but MPO activity, p<0.05 *, 
Kruskal-Wallis one-way ANOVA followed by Dunn’s multiple-comparison test). 
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Supplementary Figure 4  
Reduction of histology scores in Gpr4 -/- /IL-10 -/- male mice.  
The total histology scores of distal colon for male Gpr4 -/- /IL-10 -/-, Gpr4 +/+ 
/IL-10 -/- and Gpr4 +/+ /IL-10 +/+ mice at 80 days of age were shown, indicating 
reduced inflammation in Gpr4 -/- /IL-10 -/- mice (p<0.05, Gpr4 -/- /IL-10 -/- 
compared to Gpr4 +/+ /IL-10 -/-). H&E staining sections (top panel) showed the 
significant difference in the damage of epithelial integrity and intensity of the 
leukocyte infiltration into inflamed sites. The total histology scores are 
representative for overall histology scores of distal colon (epithelial injury plus 
leukocytes infiltration). Data are presented as mean ± SEM; n ≥ 5 per group; p 
<0.05 *, p <0.01 **, p <0.001 ***. 
 
 
Supplementary Figure 5  
Suppression of IFN-γ-producing CD4+ T helper cells in Gpr4 -/- /IL-10 -/- 
mice. Dot plots of the expression of CD4+ vs. CD8+ in LPLs isolated from 
female Gpr4 -/- /IL-10 -/-, Gpr4 +/+ /IL-10 -/- and Gpr4 +/+ /IL-10 +/+ mice are shown. 
LPLs were isolated and stained with anti-CD4 conjugated to PB-Alexa 405 and 
with anti-CD8 conjugated to APC-Cy7 and analyzed by FACS. Representative 
FACS results from more than 5 qualitatively similar experiments are shown; 
isolated LPLs from 3 female mice were pooled in each group. 
 
 
Supplementary Figure 6  
Analysis of mRNA expression profiles of cytokines in colon and 
mesenteric lymph nodes in female Gpr4 -/- /IL-10 -/- and Gpr4 +/+ /IL-10 -/- 
mice . (A) The mRNA expression profiles of IL-18, SELE, CCL20, VCAM-1, 
and COX-2 were analyzed by semi-quantitative RT-qPCR in colon tissue from 
of all three female strains (Gpr4 -/- /IL-10 -/-, Gpr4 +/+ /IL-10 -/- and Gpr4 +/+ /IL-10 
+/+ mice). (B) mRNA expression profiles of iNOS, TNF-α, IFN-γ, IL-6, CXCL1, 
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CXCL2, CCL20, MCP-1, VCAm-1, COX-2 in lymph nodes from same animals. 
(P< .05 *, Kruskal-Wallis one-way ANOVA followed by Dunn’s 
multiple-comparison test). Data are presented as relative expression 
normalized to the house-keeping gene GAPDH, n = 6-9 mice per group. Data 
are presented as mean ± SEM.  
 
Supplementary Figure 7  
The mRNA expression profile of cytokines in colon (A) and mesenteric 
lymph nodes (B) between Gpr4 -/- /IL-10 -/- and Gpr4 +/+ /IL-10 -/- male mice. 
iNOS, TNF-α, IFN-γ, IL-6, MCP-1, IL-18, CXCL2, CCL20, CXCL1, SELE, 
VCAM1 and COX-2 of all three male strains (Gpr4 -/- /IL-10 -/-, Gpr4 +/+ /IL-10 -/- 
and Gpr4 +/+ /IL-10 +/+ mice) were determined by real time RT-PCR Taqman 
assay. Data represent copies of cytokine mRNA/GAPDH and mRNA 
amplification was representative of 6~9 mice per group. The homogenate of 
each mouse was tested in triplicates. Data are presented as mean ± SEM; p 
<0.05 *, p <0.01 **, p <0.001 ***. 
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Abstract 
Objective:  A novel family of proton sensing G-protein coupled receptors (GPCRs), including 
OGR1, GPR4, and TDAG8 was identified to be important for physiological pH homeostasis 
and inflammation. Thus we determined the function of proton-sensing OGR1 in the 
intestinal mucosa. 
Design: OGR1 expression in colonic tissues was investigated in controls and IBD patients. 
Expression of OGR1 upon cell activation was studied in the Mono Mac 6 (MM6) cell line and 
primary human and murine monocytes by real-time PCR. Ogr1 knockout mice were 
crossbred with Il-10 deficient mice and studied over 200 days. Microarray profiling was 
performed using Ogr1
-/- 
and Ogr1
+/+ 
(WT) residential peritoneal macrophages.  
Results: IBD patients expressed higher levels of OGR1 in the mucosa than non-IBD controls. 
Treatment of MM6 cells with TNF, led to significant up-regulation of OGR1 expression, 
which could be reversed by the presence of NF-κB inhibitors. Kaplan-Meier survival analysis 
showed a significantly delayed onset and progression of rectal prolapse in female Ogr1
-/-
// 
Il-10
-/-
 mice. These mice displayed significantly less rectal prolapses. Up-regulation of gene 
expression, mediated by OGR1, in response to extracellular acidification in mouse 
macrophages was enriched for inflammation and immune response, actin cytoskeleton, and 
cell adhesion gene pathways.  
Conclusion: OGR1 expression is induced in cells of human macrophage lineage and primary 
human monocytes by TNF. NF-κB inhibition reverses the induction of OGR1 expression by 
TNF. OGR1 deficiency protects from spontaneous inflammation in the Il-10 KO model. Our 
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data indicate a pathophysiological role for pH-sensing receptor OGR1 during the 
pathogenesis of mucosal inflammation. 
Word count 249  
Key Words: GPCR; pH-sensing receptors; OGR1; IBD; microarrays; animal model  
Abbreviations:  CD, Crohn's disease; DSS, dextran sulphate sodium; GAPDH, glyceraldehyde-
3-phosphate dehydrogenase; GPCR, G protein coupled receptor; GPR4, G protein coupled 
receptor 4; GPR65, G protein coupled receptor 65; GPR68, G protein coupled  receptor 68; 
H&E, hematoxylin and eosin; HPRT, Hypoxanthine-guanine phosphoribosyltransferase; IBD, 
inflammatory bowel disease; IFN-γ, interferon gamma; IL, interleukin; MPO, 
myeloperoxidase; OGR1, ovarian cancer G-protein coupled receptor 1; OR, odds ratio; PBS, 
phosphate buffered saline; RT-PCR, reverse transcription polymerase chain reaction; TDAG8, 
T-cell death associated gene 8;  TNF, tumour necrosis factor; UC, Ulcerative colitis 
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INTRODUCTION  
The mechanisms involved in the maintenance of mucosal homeostasis are important in our 
understanding of the pathophysiology of inflammatory bowel disease (IBD). Both forms of 
the disease, Crohn’s disease (CD) and ulcerative colitis (UC), give rise to inflammation that is 
associated with extracellular acidification of mucosal tissue. Mucosal inflammation is 
interpreted as a local response to tissue damage and microbial invasion. 
A number of studies suggest that an acidic environment affects the progression and 
resolution of inflammation.
1-3
 Inflammation has been attributed to an increase in local 
proton concentration and lactate production
4
 and subsequent pro-inflammatory cytokine 
production, such as tumour necrosis factor (TNF), interleukin-6 (IL-6), interferon-gamma 
(IFN-γ) and interleukin-1-beta (IL-1β). TNF is one of the characterizing cytokines in IBD
5, 6
 and 
anti-TNF targeted therapies are successful in both CD and UC.
7-10
 Activated macrophages, 
which are key cellular mediators of acute and chronic inflammation, are primary producers 
of TNF
11
. TNF activates the nuclear transcription factor kappa B (NF-κB), one of the key 
regulators in chronic mucosal inflammation.
12, 13
 
G-protein-coupled receptors (GPCRs), cell-surface molecules involved in signal transduction, 
are targeted by key inflammatory cytokines.
14
 The ovarian cancer G-protein coupled 
receptor 1 (OGR1) family of receptors, which include OGR1, G protein coupled receptor 4 
(GPR4), and T-cell death associated gene (TDAG8), sense extracellular protons through 
histidine residues located on the extracellular region of the receptors, resulting in the 
modification of a variety of cell functions.
15, 16
 Early signaling pathways of pH-sensing 
receptors triggered by acidification include phospholipase C activation, inositol 
trisphosphate formation and subsequent Ca
2+
 release
15
 or cyclic adenosine monophosphate 
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(cAMP) production.
17, 18
 The increase of intracellular calcium influx and accumulation of 
cAMP has been shown to regulate a vast range of cellular responses. Moreover, OGR1 and 
TDAG8 are alleged to act in opposition in a regulatory manner, either enhancing or 
inhibiting the production of proinflammatory cytokines respectively.
19
 
TDAG8 mediated extracellular acidification inhibited lipopolysaccharide (LPS)-induced 
production of TNF and IL-6 in mouse peritoneal inflammatory macrophages.
2
 Patients with 
CD demonstrate a defect in macrophage function resulting in an inadequate bacterial 
clearance from inflammatory sites.
20
 In addition, macrophages from CD patients showed 
impaired TNF-alpha secretion in response to bacterial challenge.
21
 Furthermore, association 
results and in silico analysis have recently identified a locus within the TDAG8 gene as one of 
the susceptibility loci associated with CD.
22
 Onozawa et al. suggest that TDAG8 is a negative 
regulator of inflammation
23
, which is mediated via a Gs-coupled mechanism.
2
 In contrast, 
OGR1 is reported to act predominately via a Gq-coupled mechanism to stimulate 
proinflammatory cytokines production upon extracellular acidification.
19
 
To date, few data on the role of OGR1 in inflammation in IBD have been published. OGR1 
may play an important role in the regulation of the inflammatory pathways in IBD, and it 
may represent an interesting target for innovative therapies. Therefore, we investigated the 
role and function of OGR1 in gut inflammation, with a focus on myeloid cells. We used an 
immune-mediated inflammatory disease mouse model, namely interleukin-10 (Il-10) 
knockout (KO) mice, which spontaneously develop chronic colitis
24-26
 and a human 
monocyte model. We show that OGR1 expression is induced in monocytes by TNF and OGR1 
deficiency protects from spontaneous inflammation in the Il-10 KO model.  
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Materials and Methods 
Details of reagents used and methods for gene expression are provided in the 
Supplementary Materials and Methods section. 
pH experiments 
pH shift experiments were carried out in serum-free RPMI medium (1-41F24-I, Amimed), 
supplemented with 2 mM Glutamax (35050-038, Gibco), and 20 mM HEPES. The pH of all 
solutions was adjusted using a calibrated pH meter (Metrohm, Herisau, Switzerland) with 
NaOH or HCl, and the medium was equilibrated in a 5% CO2 incubator for 36 h. All data 
presented are referenced to pH measured at room temperature.  
Culture of cell lines 
The monocytic cell line MonoMac 6 (MM6, obtained from DMSZ) was cultured in RPMI 
(Sigma-Aldrich, Munich, Germany) supplemented with 10% FCS, 1% nonessential amino 
acids, and 1% oxalacetic acid–pyruvate–insulin medium supplement (Sigma-Aldrich), and 
maintained according to the American Type Culture Collection (ATCC). 
Patient tissue samples 
Primary intact colonic epithelial cell crypts were isolated from normal human colonic tissue 
of patients undergoing bowel surgery as previously described.
27
 Biopsies of human terminal 
ileum, colon, or rectum were taken from patients with CD or UC, or from control subjects 
undergoing colonoscopy for colon cancer screening. Biopsies from patients with colitis were 
taken endoscopically from inflamed areas. Written consent was obtained before specimen 
collection and studies were approved by the local ethics committee.  
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Isolation of human peripheral blood monocytes  
Normal human peripheral blood monocytes, obtained from the Swiss Red Cross Blood 
Service, were isolated from buffy coat samples, by density gradient centrifugation using 
Lymphoprep (Axis-Shield, Norway). Purification was performed using EasySep™ Human 
Monocyte Enrichment Kit without CD16 Depletion and EasySep magnet (both from Stemcell, 
Canada) according to manufacturer's instructions. The purity of the monocytes was > 85% as 
assessed by fluoroscein isothiocyanate (FITC)-labelled anti-CD14 (#557742, BD Biosciences, 
USA) by flow cytometry (data not shown). 
Animal models 
All animal experiments were performed according to Swiss animal welfare laws and were 
approved by the Veterinary Authority of Basel-Stadt and the Veterinary Office of the Canton 
Zürich, Switzerland. Ogr1
-/-
 (C57BL/6) mice, initially obtained from Deltagen, Inc. - San 
Mateo, Ca, USA, were generated as described.
28
 Il-10 
-/-
 mice (C57BL/6) mice and Ogr1
-/- 
mice were crossed to generate Ogr1 
-/-
 /Il-10 
-/-
 colitis susceptible mice. Mice were observed 
until reaching either 200 days of age or suffering a prolapse. All mice were housed together 
in one room in a vivarium. 
Genomic DNA extraction and genotyping  
Genotyping was confirmed by PCR of tail genomic DNA. DNA extraction was performed 
according to standard NaOH methods. The PCR reactions used for Ogr1 genotyping were 
performed as previously described
28
, oligonucleotides used are listed in the supplementary 
material and methods. 
Murine macrophage isolation and culture  
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Mature quiescent macrophages were isolated from the mouse peritoneal cavity without the 
aid of eliciting agents, as described by Zhang et al.
29
 Animals were sacrificed by cervical 
dislocation to reduce influence on pH. Further details are described in the supplementary 
methods. 
Evaluation of inflammation in murine colitis 
Typical inflammatory parameters were evaluated as previously described.
30, 31
 
Expression Profiling by Microarrays  
Global whole-transcript analysis was performed using a GeneAtlas microarray system 
(Affymetrix) to compare response differences between Ogr1
+/+ 
and Ogr1
-/- 
murine 
macrophages after 24 h acidic pH shift. Mature murine quiescent peritoneal macrophages 
were isolated as described above, from age matched female Ogr1 
-/- 
and Ogr1 
+/+ 
mice 
(C57BL/6). Five replicates or mice per condition were used, and ≈ 1 x 10
6
 macrophages/per 
mouse obtained. Cells were not pooled. Cells were treated with pH 6.7 equilibrated medium 
to activate Ogr1, and pH 7.7 to serve as negative controls. Cells were collected, and RNA and 
cDNA samples prepared. Biotin-labelled cDNA samples were hybridized to GeneChip Mouse 
Gene 1.1ST Array Strip (Affymetrix, P/N 901628) following protocols provided by Affymetrix. 
Data was summarized on gene-level using RMA (Robust Multi-array Average). Data quality 
was assessed using the bioconductor/R package 'arrayQualityMetrics'
32
 and reproducibility 
was assessed using Pearson's correlation for all the filtered expression values and 
hierarchical clustering. For all pairwise comparisons, differentially expressed genes were 
selected using ≥2.0-fold-change, P<0.05 significance, as determined using ANOVA (as 
implemented by the R package, Linear Models for Microarray Data, 'limma') and F-test for 
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 10
the complete experimental design. The results were analyzed by global ranked fold change 
and using Metacore software for pathway enrichment. 
Statistical Analysis  
For murine prolapse ratio comparison studies, statistical differences between genotypes 
were calculated by chi-square test with Fisher’s exact test (exact significance, two sided) and 
risk estimate test from contingency tables. The prolapse survival analysis was performed 
using Kaplan-Meier survival analysis (log rank Mantel-Cox test) and estimated median 
survival time. Groups of data were compared using nonparametric Mann-Whitney U-test 
(mouse data) or Kruskal-Wallis one-way ANOVA followed by Dunn’s multiple-comparison 
test (patient data). Data are pres nted as mean ± SEM for a series of n experiments. 
Probabilities (p, two tailed) of p < 0.05 were considered statistically significant. 
Monocyte/macrophage expression data were analyzed using a one-way analysis of variance 
(ANOVA) followed by the Tukey Post Hoc test. Throughout this manuscript, asterisks denote 
significant differences at *=p<0.05, **=p<0.01, ***=p<0.001. 
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RESULTS 
OGR1 mRNA expression is increased in IBD patients  
OGR1 mRNA expression in isolated crypts and terminal ileum, colon, or rectum specimens 
from IBD patients and control subjects was confirmed by RT-qPCR. Ct values from the 
isolated crypts from 4 patients ranged from 27 to 30, indicating moderate expression of 
OGR1 in colonic epithelium (data not shown). Compared with normal control subjects, OGR1 
expression increased 2.3 -fold (p<0.05) in UC patients (n=8) and 2.2 -fold (p<0.01) in CD 
patients (n=29) (Figure 1).  
OGR1 expression is regulated by TNF in myeloid cells 
A local decrease in pH usually occurs at inflammatory sites, and monocytes are rapidly 
recruited, followed by an increase in pro-inflammatory cytokines. MM6 cells were treated 
with IFN-γ, IL-1β, IL-6, TNF or TGF-β, which are known to initiate immune and inflammatory 
responses in the mucosa. Stimulation by TNF resulted in significant up-regulation of OGR1 
expression (≈4-5-fold p<0.001, Figure 2A-B).  No induction of OGR1 occurred by IFN-γ, IL-1β, 
IL-6 or TGF-β at 6 h (Figure 2A-B)  or at 1 h, 5 h or 24 h (data not shown). A concentration-
dependent (0, 2.5, 10, 25, 50, 100 ng/ml) induction of OGR1 mRNA expression in MM6 cells 
by TNF was confirmed at 4 and 8 h (Figure 2C). Maximal OGR1 induction, after 8 h treatment 
was reached at TNF concentration 50 ng/ml (Figure 2C). Induction of OGR1 expression in 
MM6 cells by TNF returned to basal levels after 48 h (Figure 2D).  
Treatment of MM6 cells with PMA, a known PKC activator but also commonly used to 
differentiate monocytes into macrophage-like cells
33
, led to increased OGR1 expression (14 
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-fold at 24 h, p< 0.001) (Figure 2E).  
To confirm the relevance of our findings in MM6 cells, we tested OGR1 -induction by TNF 
and PMA in primary human monocytes and mouse peritoneal macrophages. Concentration-
dependent TNF and PMA induction of OGR1 mRNA was confirmed in human monocytes 
(Figure 3A-B). Similarly TNF -mediated OGR1 induction was observed in mouse macrophages 
(Figure 4). The intensity of the response to TNF was comparable in MM6 cells and primary 
mouse macrophages (Figure 2C-D MM6; Figure 4). The induction time of primary human 
monocytes was considerably slower but of similar intensity. Similarly, primary human 
monocytes exhibited a slower induction and lower response to PMA compared to MM6 
cells. No induction of the other pH-sensing GPCRs GPR4 and TDAG8, by any of the cytokines 
tested or by PMA was detected (data not shown).  
TNF, LPS or PMA induced OGR1 expression is reversed by Akt, MAP and PKC kinase and 
NF-κB inhibitors 
To understand the pathways involved in TNF, PMA or LPS-mediated induction of OGR1 
expression we investigated the roles of Akt1/2 kinase, c-Jun N-terminal kinase (JNK) and PKC 
by using their specific inhibitors. Mitogen-activated protein kinases (MAPKs) play an 
important role in regulating the cellular response to various extracellular stimuli.
34
 Signaling 
via PKC is known to activate MAPKs.
35
 Activation occurs by sequential phosphorylation by 
JNK, ERK (extracellular-signal-regulated kinase) 1/2, p38 MAPK, ERK5 and ERK3/4.
36
 
Activated MAPK kinase pathways may stimulate activator protein 1 (AP-1).
37,38
 Exposure of 
monocytes and macrophages to TNF, LPS and PMA results in activation of the AP-1, NF-κB, 
caspase and MAPK pathways.
39, 40
  Akt is a serine-threonine kinase and has been implicated 
in TNF-mediated activation of NF-κB.
41, 42
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 13
Based on our time course experiments (Figure 2D), cells were stimulated with PMA, TNF or 
LPS, in the presence of the appropriate kinase inhibitor, A6730 (9 μM), SP600125 (20 μM) 
and curcumin (25 μM), and harvested after 6 hours. 
Exposure of MM6 cells to PMA, TNF and LPS induced OGR1 expression 13.7, 8.2 and 10.3 -
fold respectively. The Akt1/2 kinase inhibitor, A6730, significantly decreased TNF and LPS -
induced OGR1 expression, by 5.6 (68%) and 8.2 -fold (80%) respectively, but with less effect 
on PMA activation (4.8 -fold decrease, 35% decrease) (n=2, p<0.001 or 0.01, Figure 5A). 
SP600125, a JNK inhibitor, decreased OGR1 induction by PMA 10.1 -fold, (73%) TNF 4.0 -fold 
(48%) and LPS 7.5 -fold (80%). These results suggest that the JNK/AP1 pathway may be 
involved in OGR1 regulation. Curcumin is a potent inhibitor of protein kinase C
43
 and inhibits 
NF-κB activation through inhibition of IκB kinase and Akt activation.
44
 Curcumin abolished 
the induction of all three activating agents (PMA 12.7 -fold (93%), TNF 7.2 -fold 87% and LPS 
9.9 -fold 96% decrease). These preliminary kinase inhibitor studies suggest that Akt1/2, JNK, 
PKC and IKK pathways play an important role in the induction of OGR1 expression by PMA, 
TNF and LPS.  
Prompted by the results we next tested a number of known NF-κB inhibitors. TNF-, PMA-, or 
LPS-mediated induction of OGR1 was significantly reduced by simultaneous treatment of 
cells with NF-κB inhibitors: curcumin (25 μM), MG-132 (20 μM), AICAR (0.5 nM), BAY-11-
7082 (20 μM), CAY10512 (0.3 μM), and SC-514 (25 μM) (Figure 5A-C).  In the presence of the 
inhibitor MG132, TNF induced OGR1 expression decreased 3.2 and 5.7 -fold respectively 
(TNF 95% decrease, PMA 89% decrease) (n=2, p< 0.001, Figure 5B).  
AICAR (5-Aminoimidazole-4-carboxyamide) ribonucleoside blocks the expression of pro-
inflammatory cytokines genes by a reduction in NF-κB DNA-binding activity
45
. BAY-11-7082 
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 14
and SC-514 block NF-kB activation by inhibition of IκB kinase.
46, 47
 The resveratrol analog 
CAY10512 is a specific NF-κB inhibitor. Treatment with PMA, TNF or LPS resulted in 10.2, 3.0 
or 7.6 -fold increase in OGR1 expression respectively, but in the presence of the NF-κB 
inhibitors induction of OGR1 significantly decreased. OGR1 expression decreased with 
inhibitor; AICAR 9.3-, 2.6- and 7.3 -fold / (91%, 88%, 96%) ; BAY 7082, 9.0-, 2.6- and 6.1 -fold 
/ (88%, 87%, 81%); Cay 10512, 5.6-, 1.8- and 3.8 -fold / (56%, 62%, 49%), ; SC-514, 8.7-, 2.7- 
and 7.4 -fold (85%, 91%, 97%) on PMA, TNF and LPS stimulation, respectively (Figure 5C). 
The results collectively suggest that NF-κB plays a key role in the regulation of OGR1. 
In silico analysis of the OGR1 promoter 
As the inhibitor studies suggested a strong role for AP-1
48
 and NF-κB in the regulation of 
OGR1 expression we next performed an in silico promoter analysis of OGR1. Two alternative 
predicted promoter variants ≈ 9 kpb apart, exist for the OGR1 gene on chromosome 14. In 
silico analysis using MatInspector software
49
 (http://www.genomatix.de/matinspector.html) 
revealed several putative DNA-binding sites for AP-1, NF-κB and HIF-1α within the proximal 
regions of the OGR1 promoter variants. A schematic representation of these sites (TBSs) for 
OGR1 variants 1 and 2 and binding sites are shown in Supplemental Figure S1 and S2, 
respectively. 
Cellular responses upon OGR1 activation by extracellular acidification in murine 
macrophages. 
We further investigated the effect of OGR1 deficiency on intestinal inflammation. We 
conducted a microarray study and compared the global gene expression of wild type Ogr1
+/+
 
cells to Ogr1
-/- 
cells in response to extracellular acidification. We selected the top 100 most 
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 15
differentially expressed genes by comparing the ranked fold change upon pH shift in WT 
compared to KO macrophages. Figure 6A shows a heat map summarizing gene expression 
across all samples in the 4 experimental conditions for these 100 genes. 
Acid-induced OGR1-mediated differentially up-regulated genes in WT macrophages 
compared to OGR1 KO macrophages include inflammatory response genes (Tnfrsf13c, Ccl24, 
Cxcl13, C1qa, Nr4a1) and immune response genes (Iglv1, Cd79a, H2-Eb1, Tinagl1, Lst1, 
C1qa, C1qb Cd83, Ccl17). Furthermore, genes associated with adhesion and ECM (Sparc, 
Cyr61, Timp1, Aebp1, Ebp1, Siglec1, Cdh2, Mmp11, Serpine2, Tgm2), and actin cytoskeleton 
(Inhba, Fscn1, Sorbs2, Tuba1c, Map1b, Parva, Cnn3) were up-regulated by acidic activation 
of OGR1 in WT but not in OGR1 KO macrophages. Interestingly, cholesterol homeostasis 
genes, (Cyp11a1, Ephx2), glucose response and insulin processing genes, (Inhba, Cpe, Cma1, 
Igfbp7, Htra1, Sfrp4), differentiation and bone development gene Bmp-2 and transcription 
factor gene Nrbf2 also increased in WT Ogr1
+/+ 
compared to Ogr1
-/- 
KO cells at acidic pH.  
The scatter plot represents the ratio fold change low to high pH OGR1 KO /fold change low 
to high pH WT macrophages (Figure 6B). The top 100 differentially expressed genes are 
shown in Supplementary Tables S2.A–B. In addition, a list of genes and enrichment 
pathways, generated in GeneGo by comparison of pairs of WT low pH vs. high pH to OGR1 
KO low pH vs. high pH, is shown in supplementary Table S3 and Figure S3 respectively. 
Results discussed in this paper have been deposited in the NCBI Gene Expression Omnibus 
(GEO) Accession No. GSE60295 (http://www.ncbi.nlm.nih.gov/projects/geo). 
OGR1 deficiency protects from development of spontaneous colitis in mice 
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 16
To investigate whether the OGR1 dependent changes upon acidification have functional 
consequences during IBD, we applied a mouse model of spontaneous colitis. Analysis of the 
occurrence of prolapse in the colon over the course of 200 days showed that, only 16.7% of 
female Ogr1
-/-
/Il-10
-/-
 mice (n=24) developed rectal prolapse. The incidence was significantly 
lower than that of female Ogr1
+/+
/Il-10
-/-
 littermate mice (66.7%, n=12) maintained in the 
same vivarium room during the same time period (p = 0.007**; Odds Ratio for female mice 
Ogr1 
-/-
/Ogr1
+/+
 = 0.100 (95% CL 0.020~0.500), chi-square test with Fisher’s exact test with 
two sides). Kaplan-Meier survival analysis showed a significantly delayed onset and 
progression of rectal prolapse in female Ogr1
-/-
/Il-10
-/-
 mice (estimated median survival 
time: >200 days vs. 123 days for female Ogr1
+/+
/Il-10
-/-
 mice, p=0.002 **, log rank (Mantel-
Cox) test) (Figure 7). No prolapses were observed in control Ogr1
+/+
/Il-10
+/+
 mice (n > 100 
animals). 
Histologically, consistent with the prolapse ratios, Ogr1
-/-
/Il-10
-/-
 mice showed less 
inflammation (score 3.7±1.03) (Figure 8A), however, this difference did not reach statistical 
significance from Ogr1
+/+
/ll-10 
-/-
 female mice (6.5±1.12) (p>0.05, Figure 8B).  The same 
trend in MPO levels of female Ogr1 
-/-
/Il10
-/-
 mice was observed (0.12±0.034 vs. 0.41±0.072, 
p>0.05, Figure 9A). There were no differences in colon length, relative spleen weight (Figure 
9B-C) and in cytokines mRNA expression levels (Figure 10). 
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Discussion   
Our manuscript provides evidence for a role of the pH-sensing receptor OGR1, in 
inflammatory processes such as intestinal inflammation. We show that OGR1 mRNA 
expression is up-regulated ≈ 2 -fold during intestinal inflammation in IBD patients. To what 
extent this translates into up-regulated protein expression cannot currently be assessed due 
to a lack of suitable antibodies. We further show that the pro-inflammatory cytokine TNF, a 
major mediator in IBD associated inflammation induces OGR1 expression in human and 
murine myeloid cells. TNF up-regulates OGR1 expression for short periods (6 to 12 h), 
however, the effect is not sustained for longer periods, after 24 - 48 h OGR1 expression 
returns to basal levels.  
Similar to our findings, Lum and coworkers reported that expression of GPR4, a related 
proton sensing GPCR, is up-regulated several-fold by TNF and H2O2 in human brain 
microvascular endothelial cells.
50
 TNF-mediated induction of GPR4 occurred after 2 h and 
was sustained for 24 h.
50
 However, in contrast to OGR1, we did not observe induction of 
GPR4 and TDAG8 expression upon treatment with TNF, PMA, or LPS in MM6 cells. OGR1 
expression induced by TNF, PMA or LPS was prevented by treatment with PI-3 (Akt1/2), 
MAP and PKC inhibitors and with NF-κB inhibitors AICAR, BAY-11-7082, CAY10512, and SC-
514. LPS stimulates production of TNF in MM6 cells.
51, 52
 
We further show that genetic deletion of OGR1 ameliorates inflammation at least in female 
mice. Acidification and signaling via OGR1 induced a multitude of cellular responses in the 
microarray analysis. In murine macrophages acid induced OGR1-mediated enriched up-
regulated genes are involved in inflammatory responses, further supporting our finding that 
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OGR1 signaling upon pH changes may play an important role in mucosal inflammation. 
Notably, up-regulation of nuclear receptor subfamily 4 group A member 1 (NR4A1, also 
known as NUR77) was detected (Supplementary Table S3). NR4A1 functions as an 
immediate early-response gene and plays a key role in mediating inflammatory responses 
in macrophages.
53
 Further affected pathways are actin cytoskeleton modulation and cell 
adhesion. This may also be relevant as anti-adhesion strategies for the treatment of IBD 
have been recently successful and vedolizumab as an antibody against α4β7 integrin 
recently has been approved for therapy of Crohn’s disease by the FDA and EMA. In an 
OGR1-overexpressing Caco2 model we also observed enrichment of inflammatory response, 
including NR4A1, actin cytoskeleton, and adhesion and ECM genes upon acidification 
(manuscript in submission). In the present study, the genes Inhba and Nr4a1 which are 
linked to the myocardin-related transcription factor (MRTF) pathway
54
, were also found to 
be strongly regulated by pH change. 
Another strongly regulated gene was activin. Activin A is released early in the cascade of 
circulatory cytokines during systemic inflammatory episodes, roughly coincident with TNF 
and before IL-6 and follistatin are elicited. Activin A protein is also elevated in IBD patients 
and in experimental colitis.
55
 Recently activin A was identified to regulate macrophage 
switch between polarization states.
56
 This skew towards a pro-inflammatory phenotype 
occurs by promoting the expression of M1 (GM-CSF) markers, and impairing the acquisition 
of M2 (M-CSF) markers, while down-regulating the production of Il-10.
56
 Furthermore, 
SPARC (Secreted protein acidic and rich in cysteine) was found to be strongly regulated by 
OGR1. SPARC is a gene whose methylation has been related to IBD.
57, 58
 SPARC exacerbates 
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colonic inflammatory symptoms in DSS-induced murine colitis. Compared to WT, SPARC KO 
mice had less inflammation with fewer inflammatory cells and more regulatory T cells.
59
 
Why would pH-sensing be so important during intestinal inflammation? Firstly, pH 
homeostasis is important for the maintenance of normal cell function. pH is normally tightly 
controlled within a narrow range. Normal pH of blood and tissue is controlled at ≈ pH 7.2- 
7.4. Maintaining homeostasis requires cells to sense their external environment, 
communicate with each other, and respond rapidly to extracellular signals. This can be 
achieved by hydrophobic molecules, ion channels, catalytic receptor and G-protein-coupled 
receptors.
60
 
Under physiological conditions there are also counterplayers of OGR1 expressed in the 
mucosal tissue. TDAG8 mediates extracellular proton-induced inhibition of proinflammatory 
cytokine production in mouse macrophages.
2
 Onozawa et al. showed that TDAG8 deficient 
mice exhibit enhanced arthritic symptoms compared to wild type animals; suggesting that 
TDAG8 attenuates inflammation by negatively regulating the function of the macrophages, T 
cells and B cells.
23
 In search for genetic components and causal genetic variants of IBD, 
genome-wide association (GWA) studies have identified numerous susceptibility regions 
that are marked by single nucleotide polymorphisms (SNPs).
22, 61, 62
 Association results and 
in silico analysis identified a locus within the TDAG8 gene as susceptibility locus in CD
22
, 
supporting that TDAG8 acts as a negative regulator of inflammation. Khor et al. propose that 
the presence of TDAG8 as an IBD-risk loci is necessary to maintain intestinal homeostasis 
due to its immune modulatory effect.
63
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To summarize, ORG1 expression is induced in human and murine myeloid cells by TNF, PMA  
and LPS; whereby simultaneous treatment with NF-κB inhibitors caused a reversal of this 
effect. Up-regulated genes induced by extracellular low pH by proton-sensing OGR1 in 
murine macrophages were enriched for inflammatory and immune response, actin 
cytoskeleton and cell adhesion genes sets. The deficiency of pH-sensing receptor OGR1 
protects from spontaneous inflammation in the Il-10 KO model. Thus, pH sensors may be 
interesting new targets for pharmacological intervention in intestinal inflammation. 
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Figure and table legends  
Figure 1. OGR1 expression in human intestinal mucosa 
IBD patients expressed higher levels of OGR1 mRNA in the mucosa as compared to controls. 
Expression levels normalized to GAPDH. Biopsy specimens were taken from 29 CD patients, 
8 UC patients and 17 non-IBD control patients. Asterisks denote significant differences from 
the respective control (*P < 0.05, **P < 0.01, ***P <0 .001). 
Figure 2. TNF and PMA induce OGR1 expression in human monocytes 
A – B. MonoMac6 (MM6) cells were treated with cytokines for 6 hours. Treatment of MM6 
cells with TNF led to significant up-regulation of OGR1. No induction of OGR1 occurred with 
other cytokines (IFN-γ, IL-1β, IL-6, TGF-β) (50 ng/ml) tested. C. Concentration-dependent 
TNF (0, 2.5, 10, 25, 50, 100 ng/ml) induction of OGR1 mRNA expression was confirmed at 4 
and 8 h. Maximal OGR1 induction was reached at TNF concentration 50 ng/ml at 8 h.  D. 
Induction of OGR1 expression by TNF (50 ng/ml) returned to basal levels after 48 h. E.  
Monocytic-macrophagic differentiation of MM6 cells with phorbol 12-myristate 13-acetate 
(PMA) (25 nM), a specific activator of protein kinase C (PKC) and NF-κB, led to a significant 
increase in OGR1 mRNA expression. Asterisks denote significant differences from the 
respective control (*P < 0.05, **P < 0.01, ***P <0 .001). Representative data of one of three 
qualitatively similar experiments shown unless indicated.  
Figure 3. TNF- and PMA-dependent induction of OGR1 mRNA in primary human 
monocytes. A. Dose-dependence of TNF (0, 2.5, 10, 25, 50 ng/ml) induction of OGR1 mRNA 
was confirmed in primary human monocytes. B. PMA (0, 5, 25, 50, 75, 100 ng/ml) induction 
of OGR1 mRNA was confirmed in primary human monocytes. Asterisks denote significant 
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differences from the respective control (*P < 0.05, **P < 0.01, ***P <0 .001). Representative 
data of one of two similar experiments shown.  
Figure 4. TNF induces OGR1 expression in murine macrophages. OGR1 induction by TNF (25 
ng/ml) was also confirmed in primary mouse residential peritoneal macrophages. Asterisks 
denote significant differences from the respective control (*P < 0.05, **P < 0.01, ***P <0 
.001). Representative data of one of three similar experiments shown.  
Figure 5. TNF-, PMA-, and LPS-mediated induction of OGR1 in MM6 cells was reversed by 
simultaneous treatment of cells with kinase and NF-kB inhibitors. A. Kinase inhibitors, 
A6730 (9 μM), SP600125 (20 μM) and curcumin (25 μM), reduced or abolished TNF (25 
ng/ml), PMA (25 nM), or LPS (1 μg/ml) mediated induction of OGR1 in MM6 cells.  B. 
Treatment with NF-kB inhibitor MG-132 (20 μM) significantly reduced TNF (50 ng/ml) or 
PMA (25 nM) mediated induction of OGR1 in MM6 cells. C. AICAR (0.5 nM), BAY-11-7082 (20 
μM), CAY10512 (0.3 μM), and SC-514 (25 μM) also reduced TNF (25 ng/ml), PMA (25 nM), or 
LPS (1 μg/ml) mediated induction of OGR1. Asterisks denote significant differences from the 
respective control (*P < 0.05, **P < 0.01, ***P <0 .001). Representative data of one of two 
similar experiments shown. 
Figure 6. Global gene expression of acid response of mouse macrophages. A. Top 100 
genes from the whole-transcript microarray analysis of acid response (pH 6.7) of wild type 
(WT) and Ogr1 KO murine macrophages. Control condition, pH 7.7 is shown on the left. 
Changes in gene expression within each comparison are represented as Log2-transformed 
fold changes (≥2.0-absolute-fold-change, P<0.05 significance). B. Differentially expressed 
genes for acid response in WT and OGR1 KO macrophages. Fold changes in low to high pH 
shift of OGR1 KO macrophages are depicted on y-axis and fold changes low to high pH WT 
Page 23 of 41 Inflammatory Bowel Diseases
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
OGR1 manuscript, Page 24 of 56
For Peer Review
de Vallière et al.   OGR1 is a regulator of intestinal inflammation 24 
 24
macrophages are shown on the x-axis. The highest ranking differentially expressed genes in 
the acid response of WT mouse macrophages are shown in the lower right quadrant of the 
scatter plot and the upper left quadrant shows the highest ranking differentially expressed 
genes in the acid response of OGR1 KO mouse macrophages.  
Figure 7. OGR1 deficient mice show delayed onset and severity of prolapse in a 
spontaneous IL-10 knock out mouse model. Kaplan-Meier survival analysis showed a 
significantly delayed onset and progression of rectal prolapse in female Ogr1 
-/-
/Il-10
-/-
 mice 
(estimated median survival time: >200 days vs. 123 days, p=0.002 **, log rank (Mantel-Cox) 
test). Green solid lines, Ogr1 
-/-
/Il-10 
-/-
 mice (16.7% prolapses, n=24); blue solid line, Ogr1 
+/+
/Il-10 
-/- 
mice (66.7% prolapses, n=12); grey solid lines, Ogr1
+/+
/Il-10
+/+ 
mice (0% prolapses, 
n=31). No rectal prolapses were detected in any of the Ogr1
+/+
/Il-10
+/+
 mice in the breeding 
colony in the study, 200 days.  
Figure 8. OGR1 deficient mice exhibit a trend to less inflammation in a spontaneous IL-10 
knock out mouse model  A. Microscopic analysis of terminal colon sections from Ogr1 
-/-
/Il-
10 
-/-
, Ogr1
+/+
/Il-10
-/- 
and Ogr1
+/+
/Il-10
+/+ 
80-day-old mice, staining by Hematoxylin and eosin. 
Representative images are shown. B. Histological score, based on evaluation of 
morphological changes of epithelium and immune cell infiltration, of distal colon from Ogr1 
-
/-
/Il-10 
-/-
, Ogr1
+/+
/Il-10 
-/- 
and Ogr1
+/+
/Il-10
+/+ 
80-day-old mice. Data presented as mean ± 
SEM; n ≥ 5 per group; Asterisks denote significant differences from the respective control 
(*P < 0.05, **P < 0.01, ***P <0 .001). All mice were female. 
Figure 9. The development of IBD and progression of prolapse between Ogr1 
-/-
/IL-10 
-/-
and Ogr1
+/+
/Il-10
-/- 
female mice. A. Comparison of MPO activity in colon tissue B. 
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Assessment of colon length. C. Relative spleen weight. No significant differences in OGR1 
KO/Il-10 KO mice and controls in these parameters were observed. 
Figure 10.  Expression levels of cytokines in colons of female Ogr1 
-/-
/Il-10 
-/-
 , Ogr1 
+/+
/Il-10 
-
/- 
and Ogr1 
+/+
/Il-10
+/+
 (WT control) mice were determined by real-time PCR and normalized 
to GAPDH. (n= 6~9 mice per group). The homogenate of each mouse colon sample was 
tested in triplicate. Data presented as mean ± SEM; Asterisks denote significant differences 
from the respective control (*P < 0.05, **P < 0.01, ***P <0 .001). No statistical difference 
between colon and mesenteric lymph nodes of female Ogr1
 -/-
/Il-10
-/- 
mice and female Ogr1 
+/+
/Il-10 
-/- 
mice was observed (p>0.05, Kruskal-Wallis one-way ANOVA followed by Dunn’s 
multiple-comparison test).  
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Figure 1. OGR1 expression in human intestinal mucosa  
IBD patients expressed higher levels of OGR1 mRNA in the mucosa as compared to controls. Expression 
levels normalized to GAPDH. Biopsy specimens were taken from 29 CD patients, 8 UC patients and 17 non-
IBD control patients. Asterisks denote significant differences from the respective control (*P < 0.05, **P < 
0.01, ***P <0 .001).  
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Figure 2. TNF and PMA induce OGR1 expression in human monocytes  
A – B. MonoMac6 (MM6) cells were treated with cytokines for 6 hours. Treatment of MM6 cells with TNF led 
to significant up-regulation of OGR1. No induction of OGR1 occurred with other cytokines (IFN-γ, IL-1β, IL-
6, TGF-β) (50 ng/ml) tested. C. Concentration-dependent TNF (0, 2.5, 10, 25, 50, 100 ng/ml) induction of 
OGR1 mRNA expression was confirmed at 4 and 8 h. Maximal OGR1 induction was reached at TNF 
concentration 50 ng/ml at 8 h.  D. Induction of OGR1 expression by TNF (50 ng/ml) returned to basal levels 
after 48 h. E.  Monocytic-macrophagic differentiation of MM6 cells with phorbol 12-myristate 13-acetate 
(PMA) (25 nM), a specific activator of protein kinase C (PKC) and NF-κB, led to a significant increase in 
OGR1 mRNA expression. Asterisks denote significant differences from the respective control (*P < 0.05, **P 
< 0.01, ***P <0 .001). Representative data of one of three qualitatively similar experiments shown unless 
indicated.  
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Figure 3. TNF- and PMA-dependent induction of OGR1 mRNA in primary human monocytes. A. Dose-
dependence of TNF (0, 2.5, 10, 25, 50 ng/ml) induction of OGR1 mRNA was confirmed in primary human 
monocytes. B. PMA (0, 5, 25, 50, 75, 100 ng/ml) induction of OGR1 mRNA was confirmed in primary human 
monocytes. Asterisks denote significant differences from the respective control (*P < 0.05, **P < 0.01, 
***P <0 .001). Representative data of one of two similar experiments shown.  
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Figure 4. TNF induces OGR1 expression in murine macrophages. OGR1 induction by TNF (25 ng/ml) was also 
confirmed in primary mouse residential peritoneal macrophages. Asterisks denote significant differences 
from the respective control (*P < 0.05, **P < 0.01, ***P <0 .001). Representative data of one of three 
similar experiments shown.  
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Figure 5. TNF-, PMA-, and LPS-mediated induction of OGR1 in MM6 cells was reversed by simultaneous 
treatment of cells with kinase and NF-kB inhibitors. A. Kinase inhibitors, A6730 (9 µM), SP600125 (20 µM) 
and curcumin (25 µM), reduced or abolished TNF (25 ng/ml), PMA (25 nM), or LPS (1 µg/ml) mediated 
induction of OGR1 in MM6 cells.  B. Treatment with NF-kB inhibitor MG-132 (20 µM) significantly reduced 
TNF (50 ng/ml) or PMA (25 nM) mediated induction of OGR1 in MM6 cells. C. AICAR (0.5 nM), BAY-11-7082 
(20 µM), CAY10512 (0.3 µM), and SC-514 (25 µM) also reduced TNF (25 ng/ml), PMA (25 nM), or LPS (1 
µg/ml) mediated induction of OGR1. Asterisks denote significant differences from the respective control (*P 
< 0.05, **P < 0.01, ***P <0 .001). Representative data of one of two similar experiments shown.  
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Figure 6.A Global gene expression of acid response of mouse macrophages. A. Top 100 genes from the 
whole-transcript microarray analysis of acid response (pH 6.7) of wild type (WT) and Ogr1 KO murine 
macrophages. Control condition, pH 7.7 is shown on the left. Changes in gene expression within each 
comparison are represented as Log2-transformed fold changes (≥2.0-absolute-fold-change, P<0.05 
significance).  
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Figure 6.B Global gene expression of acid response of mouse macrophages. B. Differentially expressed 
genes for acid response in WT and OGR1 KO macrophages. Fold changes in low to high pH shift of OGR1 KO 
macrophages are depicted on y-axis and fold changes low to high pH WT macrophages are shown on the x-
axis. The highest ranking differentially expressed genes in the acid response of WT mouse macrophages are 
shown in the lower right quadrant of the scatter plot and the upper left quadrant shows the highest ranking 
differentially expressed genes in the acid response of OGR1 KO mouse macrophages.  
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Figure 7. OGR1 deficient mice show delayed onset and severity of prolapse in a spontaneous IL-10 knock 
out mouse model. Kaplan‐Meier survival analysis showed a significantly delayed onset and progression of 
rectal prolapse in female Ogr1 -/-/Il-10-/- mice (estimated median survival time: >200 days vs. 123 days, 
p=0.002 **, log rank (Mantel‐Cox) test). Green solid lines, Ogr1 -/-/Il-10 -/- mice (16.7% prolapses, 
n=24); blue solid line, Ogr1 +/+/Il-10 -/- mice (66.7% prolapses, n=12); grey solid lines, Ogr1+/+/Il-
10+/+ mice (0% prolapses, n=31). No rectal prolapses were detected in any of the Ogr1+/+/Il-10+/+ mice 
in the breeding colony in the study, 200 days.  
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Figure 8. OGR1 deficient mice exhibit a trend to less inflammation in a spontaneous IL-10 knock out mouse 
model  A. Microscopic analysis of terminal colon sections from Ogr1 -/-/Il-10 -/-, Ogr1+/+/Il-10-/- and 
Ogr1+/+/Il-10+/+ 80-day-old mice, staining by Hematoxylin and eosin. Representative images are shown. 
B. Histological score, based on evaluation of morphological changes of epithelium and immune cell 
infiltration, of distal colon from Ogr1 -/-/Il-10 -/-, Ogr1+/+/Il-10 -/- and Ogr1+/+/Il-10+/+ 80-day-old 
mice. Data presented as mean ± SEM; n ≥ 5 per group; Asterisks denote significant differences from the 
respective control (*P < 0.05, **P < 0.01, ***P <0 .001). All mice were female.  
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Figure 9. The development of IBD and progression of prolapse between Ogr1 -/-/IL-10 -/-and Ogr1+/+/Il-
10-/- female mice. A. Comparison of MPO activity in colon tissue B. Assessment of colon length. C. Relative 
spleen weight. No significant differences in OGR1 KO/Il-10 KO mice and controls in these parameters were 
observed.  
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Figure 10.  Expression levels of cytokines in colons of female Ogr1 -/-/Il-10 -/- , Ogr1 +/+/Il-10 -/- and 
Ogr1 +/+/Il-10+/+ (WT control) mice were determined by real-time PCR and normalized to GAPDH. (n= 
6~9 mice per group). The homogenate of each mouse colon sample was tested in triplicate. Data presented 
as mean ± SEM; Asterisks denote significant differences from the respective control (*P < 0.05, **P < 0.01, 
***P <0 .001). No statistical difference between colon and mesenteric lymph nodes of female Ogr1 -/-/Il-
10-/- mice and female Ogr1 +/+/Il-10 -/- mice was observed (p>0.05, Kruskal-Wallis one-way ANOVA 
followed by Dunn’s multiple-comparison test).  
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De Vallière et al. 
 
Supplementary Material  
The G protein-coupled pH-sensing receptor OGR1 is a regulator of intestinal 
inflammation 
 
 
Materials and Methods 
Chemicals  
Cytokines were obtained from Sigma-Aldrich (St. Louis, MA, USA), unless otherwise stated. 
TNF (#654205) was purchased from Calbiochem (Merck Darmstadt, Germany). 5-
aminoimidazole-4-carboxamide-1-beta-4-ribofuranoside (AICAR) (#100102-41), BAY-11-
7082 (#100010266), CAY10512 (#10009536), Curcumin (#81025.1), SC-514 
(Cayman#10010267), SP600125 (Cayman #100010466) were purchased from Cayman (Ann 
Arbor, Michigan, USA).  
Genomic DNA extraction and genotyping  
For PCR reactions, the oligonucleotides used were as follows:  
Il-10 genotyping: 5’-GTGGGTGCAGTTATTGTCTTCCCG-3’ (oIMR0086),  
5’-GCCTTCAGTATAAAAGGGGGACC-3’ (oIMR0087),  
5’-CCTGCGTGCAATCCATCTTG-3’ (oIMR0088),  
Ogr-1 genotyping:  
5’-ACCACC AGTGATGCCTAGATCCTG A-3’ (P416),  
5’-AAGATGACCACGGTGCTGAGC ACC A-3’ (P417),  
5’-CCATTCGACCACCAAGCG AAACAT C-3’ (R3).  
 
Murine macrophage isolation and culture  
Peritoneal murine macrophages were centrifuged, washed in PBS and resuspended in RPMI 
1640 medium containing 2 mM Glutamax (35050-038, Gibco), 10% fetal calf serum (2-
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01F120-I, Amimed, Bio Concept, Allschwil, Switzerland), 100 U/ml penicillin, 100 μg/ml 
streptomycin (all obtained from Sigma–Aldrich, Buchs, Switzerland). Cells from each mouse 
were treated without pooling, after plating in 6 well plates (≈ 3 x 106 cells in 1 ml/well) at 
37°C, 5% CO2. After 2 h, non-adherent cells were removed. Macrophages were maintained 
in RPMI medium, 5% CO2 for 24 h. Final number of cells per treatment (obtained from each 
mouse) was ≈ 1 x 106 cells.  The resulting adherent population consisted of ≈ 88% peritoneal 
macrophages as determined by flow cytometry (data not shown). 
RNA extraction and quantitative Real-Time RT-PCR.  
Human and mouse tissue.  
Tissue pieces used for RNA analysis were transferred immediately into RNAlater solution 
(Qiagen, Valencia, CA) and stored at −80°C. Tissue biopsies were disrupted in RLT buffer 
(Qiagen) using a 26G needle.  
Cells and tissue samples. Total RNA was isolated using the RNeasy Mini Kit in the automated 
QIAcube following the manufacturer’s recommendations (Qiagen, Hombrechtikon, 
Switzerland). For removal of residual DNA, DNase treatment, 15 min at room temperature, 
was integrated into the QIAcube program according to the manufacturer’s instructions. For 
cDNA synthesis, the High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems, 
Foster City, CA), was used, following the manufacturer’s instructions. Determination of 
mRNA expression was performed by quantitative real-time PCR (qRT-PCR) on a 7900HT real-
time PCR system (Applied Biosystems, Foster City, USA), under the following cycling 
conditions: 20 sec at 95 °C, then 45 cycles of 95 °C for 3 sec and 60 °C for 30 sec with the 
TaqMan Fast Universal Mastermix. Samples were analyzed as triplicates. Relative mRNA 
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expression was determined the by the comparative ∆∆Ct method1, which calculates the 
quantity of the target sequences relative to the endogenous control and a reference 
sample.  TAQMAN Gene Expression Assays, (all from Applied Biosystems, Foster City, USA), 
used in this study are listed in the online supplementary Table S1. 
Table S1. TaqMan assays 
Gene 
Symbol Gene Name Assay ID 
GPR68  Human G protein-coupled receptor 68, OGR1 Hs 00268858- s1 
GPR4 Human G protein-coupled receptor 4 Hs 00270999 - s1 
GPR65  Human G protein-coupled receptor 65, TDAG8 Hs 00269247 - s1 
GAPDH Human glyceraldehyde-3-phosphate dehydrogenase (GAPDH) Endogenous Control  4326317E 
ACTB Human ACTB (beta actin) Endogenous Control 4310881E 
HuPo  Human acidic ribosomal protein (RPLPO) Endogenous Control 4310879E 
HPRT1 Human Hypoxanthine guanine phosphoribosyl transferase 1 Hs01003268_g1 
GPR68 Mouse G protein-coupled receptor 68, OGR1 Mm00558545_s1 
GPR4 Mouse G protein-coupled receptor 4 Mm00558777_s1  
GPR65 Mouse G protein-coupled receptor 65, TDAG8 Mm00433695_m1  
CCL20 Mouse chemokine (C-C motif) ligand 20 Mm01268754_m1 
COX-2 Mouse prostaglandin-endoperoxide synthase 2 Mm00478374_m1 
CXCL1 Mouse chemokine (C-X-C motif) ligand 1 Mm04207460_m1 
CXCL2 Mouse chemokine (C-X-C motif) ligand 2 Mm00436450_m1 
IFN-γ Mouse interferon gamma Mm00801778_m1 
IL-18 Mouse Interleukin 18 Mm00434225_m1 
IL-6 Mouse Interleukin 6 Mm00446190_m1 
iNOS Mouse nitric oxide synthase 2 Mm01309893_m1 
MCP-1 Mouse chemokine (C-C motif) ligand 2 Mm00441242_m1 
SELE Mouse selectin, endothelial cell Mm00441278_m1 
TNF-α Mouse tumour necrosis factor alpha Mm99999068_m1 
VCAM1 Mouse vascular cell adhesion molecule 1 Mm01320970_m1 
GAPDH Mouse glyceraldehyde-3-phosphate dehydrogenase (GAPDH) Endogenous Control  Mm03302249_g1 
 
Human β-actin 4310881E, Human hupo, 4310879E, Human GAPDH 4326317E, Human HPRT1 (hypoxanthine 
phosphoribosyltransferase 1) Hs01003268_g1 Cat. # 4331182  
Human HuPo/ RPLP0 (large ribosomal protein) Endogenous Control (VIC / TAMRA Probe, Primer Limited), 
4310879E, Human acidic ribosomal protein (HuPO), Hypoxanthine guanine phosphoribosyl transferase 
OGR1 manuscript, Page 46 of 56
Predictive location of OGR1 Promoter Variants 1 and 2 on Chromosome 14 
Human G protein-coupled receptor 68 (GPR68), transcript variant 1, mRNA 2,880 bp linear mRNA 
Human G protein-coupled receptor 68 (GPR68), transcript variant 2, mRNA 2,834 bp linear mRNA 
 VARIANT 2 
Exon 1   
(Non-coding exon) 
72720059…..72720224 
VARIANT 1 and VARIANT 2 
Exon 2 (coding exon) 
72698876 ….72701523  
NOTE: both variants have 
the same coding sequence 
72700297….72701394 
VARIANT 1 
Exon 1   
(Non-coding exon) 
72710641…..72710852  
Figure S1. Schematic representation of the in silico-
predictions of the DNA binding sites for the 
transcription factors AP-1, HIF-1α, and NF-κB within 
the proximal regions of the OGR1 promoter variants 1 
and 2. The arrow indicates the transcription start site. 
Numbers above the boxes indicate the distance from 
the transcription start site. Numbers in red indicate 
identity of the consensus binding motive. 
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Figure S2. List of possible binding sites to the consensus elements AP-1, HIF1-α and NFκB in 
the in silico promoter analysis of OGR1. 
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Figure S3. Enrichment analysis: Meta Core (Gene Go) Pathway Maps Ontology. Pairwise 
comparison of acidified WT vs. Ogr1 KO murine macrophages. pH 6.7 24 h. Extracellular 
acidosis activation of Ogr1 in murine macrophages show that the most significantly enriched 
canonical pathways include Activin A associated pathways, immune response and actin 
cytoskeleton remodeling pathways. 
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Rank 
WT/KO 
Ratio 
Symbol Full name Involved in: 
(Reference: Gene Card, NCBI, JAX, Uniprot, 
unless otherwise indicated) 
1. Cyp11a1 Cholesterol side chain cleavage 
enzyme, mitochondrial (Cytochrome 
P450 11A1) 
Cholesterol, lipid or steroid metabolism. 
Catalyses the side-chain cleavage reaction of 
cholesterol to pregnenolone.  
2. Sparc Secreted acidic cysteine rich 
glycoprotein (Osteonectin, Basement 
membrane protein 40 (BM-40)) 
Cell adhesion, wound healing, ECM 
interactions, bone mineralization. Activates 
production and activity of matrix 
metalloproteinases. 
3. Tpsb2 Tryptase beta-2 or tryptase II  (trypsin-
like serine protease)  
Inflammatory response, proteolysis. 
4. Inhba Inhibin Beta A or Activin beta-A chain Immune response and mediators of 
inflammation and tissue repair.2-5 
5. Cpe Carboxypeptidase E Insulin processing, proteolysis.  
6. Igfbp7 Insulin-like growth factor-binding 
protein 7 
Stimulates prostacyclin (PGI2) production and 
cell adhesion. Induced by retinoic acid. 
7. Clu Clusterin Chaperone-mediated protein folding, positive 
regulation of NF-κB transcription factor 
activity. Protects cells against apoptosis and 
cytolysis by complement. Promotes 
proteasomal degradation of COMMD1 and 
IKBKB.  
8. Cma1 Chymase 1 Cellular response to glucose stimulus, 
interleukin-1 beta biosynthetic process. 
Possible roles: vasoactive peptide generation, 
extracellular matrix degradation. 
9. Sfrp4 Secreted frizzled-related protein 4 Negative regulation of Wnt signalling. 
Increases apoptosis during ovulation. 
Phosphaturic effects by specifically inhibiting 
sodium-dependent phosphate uptake.  
10. Ephx2 Bifunctional epoxide hydrolase  Cholesterol homeostasis, xenobiotic 
metabolism by degrading potentially toxic 
epoxides.  
11. Pcolce Procollagen C-endopeptidase enhancer Proteolysis. Collagen binding. Component in 
collagen and extracellular matrix. 
12. Akr1cl Aldo-keto reductase family 1, member 
C-like 
Oxidoreductase activity 
13. Cyr61 Cysteine rich protein 61 Cell adhesion, chemotaxis, cell proliferation, 
wound healing and angiogenesis. 
14. Sfrp2 Secreted frizzled-related protein 2 Differentiation, modulator of Wnt signalling 
pathway.  
15. Parm1 Prostate androgen-regulated mucin-
like protein 1 
Regulation of TLP1 expression and telomerase 
activity, enabling certain prostatic cells to 
resist apoptosis.  
16. Bcat1 Branched chain aminotransferase 1 Branched-chain amino acid biosynthetic 
process. 
17. Mgarp Mitochondria localized glutamic acid 
rich protein, Hypoxia up-regulated 
mitochondrial movement regulator 
protein 
Response to steroid hormone stimulus & 
hypoxia. Trafficking of mitochondria along 
microtubules. Aids steroidogenesis through 
maintenance of mitochondrial abundance & 
morphology. 
Table S2.A-B. Differentially expressed genes following activation of OGR1 by acidic pH in mouse 
peritoneal macrophages pH 6.7 24 h.  A.  Gene List, including gene process B. Complete Table (Excel). 
OGR1 manuscript, Page 50 of 56
de Vallière et al.   OGR1 is a regulator of intestinal inflammation 8 
 8 
18. Ppic Peptidyl-prolyl cis-trans isomerase C, 
cyclophilin C, cyp-20c 
Accelerates protein folding.  
 
19. Aldh1a1 Retinal dehydrogenase 1, aldehyde 
dehydrogenase family 1, A1 
9-cis-retinoic acid biosynthetic process. 
Converts/oxidizes retinaldehyde to retinoic 
acid. 
20. 9930013L
23RikCemi
p 
Cell migration inducing protein ER retention sequence binding, hyaluronic acid 
binding,  
21. Fscn1 Fascin homolog 1, actin bundling 
protein 
Actin filament bundle assembly, cell migration. 
Organization of actin filament bundles, 
formation of microspikes, membrane ruffles, 
and stress fibres. Associates with beta-catenin. 
22. Sorbs2 Sorbin and SH3 domain containing 2 Actin filament organization, cell adhesion, cell 
migration.   
23. Tuba1c Tubulin, alpha 1C Microtubule-based process.  
24. Leprel1 Prolyl 3-hydroxylase 2 leprecan-like 
protein 1 
Collagen metabolic process, negative 
regulation of cell proliferation.  
25. Prss35 Inactive serine protease 35 Serine protease homolog.  
26. Plscr2 Phospholipid scramblase 2 Cellular response to lipopolysaccharide.  
27. Ccnd2 Cyclin D2 Cell cycle, cell division, protein kinase binding. 
28. Serpinh1 Serpin H1  Stress response. Binds specifically to collagen. 
May be involved as a chaperone in the 
biosynthetic pathway of collagen.  
29. Iglv1 Immunoglobulin lambda variable 1 Immune Response 
30. Tnfrsf13c Tumour necrosis factor receptor 
superfamily, member 13c 
B, T cell costimulation, positive regulation of B 
and T cell proliferation, positive regulation of 
interferon-gamma biosynthetic process. 
31. Timp1 Metalloproteinase inhibitor 1,  tissue 
inhibitor of metallo-proteinase 1 
Response to cytokine, negative regulation of 
apoptotic process, wound healing. Complexes 
with metalloproteinases (such as collagenases) 
and irreversibly inactivates them by binding to 
their catalytic zinc cofactor. 
32. Rpl18a Ribosomal protein L18A Translation 
33. Cd79a CD79A antigen (immunoglobulin-
associated alpha) 
Immune response 
34. Ccl24 Chemokine (C-C motif) ligand 24 Chemotaxis, Inflammatory response, 
cytoskeleton organization 
35. Nrbf2 Nuclear receptor (NR) binding factor 2 Transcription, transcription regulation. May 
modulate transcriptional activation by target 
NRs. 
36. Gm9513 Predicted gene 9513, Secreted tfp/ly-
6/upar protein pate-p 
N/A 
37. Rpl35a Ribosomal protein L35A rRNA processing  
38. 1700022K
RikN4bp2
os 
NEDD4 binding protein 2, opposite 
strand 
N/A 
39. H2-Eb1 Histocompatibility 2, class II antigen E 
beta 
Antigen processing and presentation of 
exogenous peptide antigen via MHC class II.  
40. Map1b Microtubule-associated protein 1B Microtubule bundle formation, actin binding, 
cytoskeletal regulatory protein binding. 
41. Nrn1 Neuritin 1 Axonogenesis  
42. Tinagl1 Tubulointerstitial nephritis antigen-like 
1 
Immune response, proteolysis, cysteine-type 
peptidase activity, laminin binding. 
43. Gm11937 Predicted gene 11937 Fibrous proteins rich in cysteine, keratin. 
44. Olfr1004p
s1 
Olfactory receptor 1004, pseudogene 1 Olfactory receptor  
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45. Cxcl13 Chemokine (C-X-C motif) ligand 13 Chemotaxis, Inflammatory response.  
46. Htra1 Htra serine peptidase 1 or insulin-like 
growth factor binding protein 5 
protease 
 
 
Negative regulation of defense response to 
virus, TGFβ receptor and BMP signalling 
pathway 
47. Parva Parvin, alpha Actin cytoskeleton reorganization, actin-
mediated cell contraction, cell polarity, 
substrate adhesion-dependent cell spreading, 
directed cell migration. 
 
48. Aebp1 AE binding protein 1, Adipocyte 
enhancer-binding protein 1 
Cell adhesion, proteolysis. Isoform 2 may 
positively regulate NF-κB activity in 
macrophages by promoting phosphorylation 
and degradation of  
Iκ-B-α (NFKBIA), leading to enhanced 
macrophage inflammatory responsiveness. 
49. Lst1 Leukocyte specific transcript 1 Cell shape, immune response. Induces 
filopodia and microspikes, may be involved in 
dendritic cell maturation 
50. Psmb5-ps Proteasome (prosome, macropain) 
subunit, beta type 5, pseudogene 
Proteasome-mediated ubiquitin-dependent 
protein catabolic process, response to 
oxidative stress. 
51. Trav13-2 T cell receptor alpha variable 13-2  
52. Krtap6-2 Keratin associated protein 6-2 Hair keratin-associated protein gene 
53. Kcng2 Potassium voltage-gated channel, 
subfamily G, member 2 
Potassium ion transmembrane transport 
54. Dab2 Disabled 2, mitogen-responsive 
phosphoprotein 
Apoptosis, Differentiation, Endocytosis, 
Protein transport, Transport, Wnt signalling.  
55. Atp2a3 Endoplasmic reticulum (ER)  
Ca2+ ATPase 3  
Ca2+ transport, ion transport. Mg2+-dependent 
enzyme, catalyses hydrolysis of ATP coupled 
with transport of Ca2+. Transports Ca2+ from 
cytosol into  sarcoplasmic/ER lumen 
56. Siglec1 Sialic acid binding Ig-like lectin 1, 
sialoadhesin 
Cell adhesion, endocytosis 
57. Gm6816 
(Rps4lps) 
Ribosomal protein S4-like, pseudogene Translation 
58. Mmp11 Matrix metallopeptidase 11 Basement membrane organization, Ca2 
binding, metalloendopeptidase activity, Zn2+- 
binding 
59. Fdx1 Ferredoxin 1 Cholesterol metabolic process, hormone 
biosynthetic process 
60. Adamts1 ADAM metallopeptidase with 
thrombospondin type 1 motif, 1 
Inflammatory response  
61. Fbxo32 F-box protein 32 Protein ubiquitination  
62. Uck2 Uridine-cytidine kinase 2 UMP, CTP salvage, cellular response to oxygen 
levels.  
63. Tm4sf19 Transmembrane 4 L six family member 
19 
N/A 
64. Gm10334 Predicted gene 10334 Proteolysis 
65. Rps2-ps13 Ribosomal protein S2, pseudogene 13 N/A  
66. Slc16a2 Solute carrier family 16 
(monocarboxylic acid transporters), 
member 2 
Symporter activity 
67. Cdh2 Cadherin-2 Cell adhesion, calcium-dependent. 
68. Gm13375 Predicted gene 13375 N/A 
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69. Kifc5b Kinesin family member C5B Microtubule binding and microtubule motor 
activity. 
70. Slc7a8 Solute carrier family 7 (cationic amino 
acid transporter, y+ system) member 8 
 
Large and neutral amino acid transmembrane 
transport. 
71. C1qa Complement component 1, q 
subcomponent, alpha polypeptide 
Complement activation, classical pathway, 
immune system process, 
72. Gm10540 Predicted gene 10540 N/A 
73. Gm10153 Predicted gene 10153 N/A 
74. Tsga10ip Testis specific 10 interacting protein 
 
 
N/A 
75. Cir1 Corepressor interacting with RBPJ, 1 
Recombining binding 
proteinsuppressor of hairless  
Required for RBPJ-mediated repression of 
transcription 
 
76. Hmgb3 High mobility group box 3 Negative regulation of myeloid cell 
differentiation 
77. Ormdl3 ORM1-like 3 Ceramide metabolic process. Negative 
regulator of sphingolipid synthesis. May 
indirectly regulate endoplasmic reticulum-
mediated calcium signalling 
78. 5430421N
21Rik 
RIKEN cdna 5430421N21 gene Human homolog KRT83, keratin 83, 
intermediate filament (cytoskeleton) 
79. Krt8 Keratin, type II cytoskeletal 8, 
cytokeratin8 
Maintains cellular structural integrity and 
cellular differentiation. TNF-mediated 
signalling pathway.  
80. Cnn3 Calponin 3, acidic Thin filament-associated protein. Binds to 
actin, calmodulin, troponin C and tropomyosin. 
Interaction of calponin with actin inhibits 
actomyosin Mg-ATPase activity. 
81. Acsf2 Acyl-CoA synthetase family member 2 Acyl-CoA synthases catalyze the initial reaction 
in fatty acid metabolism.  
82. F2r F2r coagulation factor II (thrombin) 
receptor, (Proteinase-activated 
receptor 1 (PAR1)) 
Regulation of thrombotic response. 
83. C1qb C1qb complement component 1, q 
subcomponent, beta polypeptide 
Immune and stress response. 
84. Cd83 CD83 antigen Immune response, antigen presentation and 
cellular interactions that follow lymphocyte 
activation 
85. Vmn2r4 Vomeronasal 2, receptor 4 GPCR, putative pheromone receptor. 
86. Hs6st2 Heparan sulfate 6-O-sulfotransferase 2 Heparan sulfate proteoglycans are molecules 
in cell surface, ECM & basement membranes. 
Involved in cell growth, differentiation, 
adhesion, and migration. Hs6st2 catalyzes the 
transfer of sulfate to HS. 
87. Gm9025 Predicted gene 9025  
88. H2-Aa H2-Aa histocompatibility 2, class II 
antigen A, alpha 
Immune response 
89. Vmn1r59 Vomeronasal 1 receptor 59 GPCR, pheromone receptor. 
90. Serpine2 Serpine2 serine (or cysteine) peptidase 
inhibitor, clade E, member 2 
Serine protease inhibitor with activity toward 
thrombin, trypsin, and urokinase. Promotes 
neurite extension by inhibiting thrombin. Binds 
heparin. 
91. Hsd3b1 Hydroxy-delta-5-steroid 
dehydrogenase, 3 beta- and steroid 
delta-isomerase 1 
Possible steroid biosynthetic process 
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92. Ube2c Ubiquitin-conjugating enzyme E2C Ubiquitin-protein ligase activity 
93. Mcpt4 Mast cell protease 4 Proteolysis 
94. Tgm2 Transglutaminase 2, C polypeptide Protein crosslinking 
95. Ptgs1 Prostaglandin-endoperoxide synthase 
1 (COX-1) 
 
96. Txlng Taxilin gamma Intracellular vesicle trafficking 
97. Igkv8-30 Immunoglobulin kappa chain variable 
8-30 
Immune response 
98. Lsm6 Lsm6 homolog, U6 small nuclear RNA 
associated (S. cerevisiae) 
Involved in RNA processing 
99. Gm4968 Predicted gene 4968  
100. Ccl17 Chemokine (C-C motif) ligand 17 Induces chemotaxis in T cells 
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Table S3. Differentially expressed genes (≥2.0-absolute-fold-change, P<0.05) following 
proton activation of OGR1 in murine macrophages. pH 6.7 24 h.  
 
 
 
 
 
 
 
 
 
Entrez 
Gene No. Symbol/gene Gene Name 
20344 Selp Selectin P (Granule Membrane Protein 140kDa) 
13653 Egr1 Early Growth Response 1 
20299 Ccl22 Chemokine (C-C Motif) Ligand 22 
12156 Bmp2 Bone morphogenetic protein 2 
18787 PAI-1 Serpine1 
57349 Ppbp Pro-platelet basic protein (chemokine (C-X-C motif) ligand 7) 
23886 Gdf15 Growth Differentiation Factor  
14131 Fcgr3 Fc receptor, IgG, low affinity III (CD16) 
246256 Fcgr4 Fc receptor, IgG, low affinity IV (CD16-2) 
15370 Nr4a1 Nuclear receptor subfamily 4 
20343 Sell Selectin, CD62L 
54123 Irf7 Interferon Regulatory Factor 7 
21825 Thbs1 Thrombospondin 1 
67603 Dusp6 Dual Specificity Phosphatase 6 
29817  Igfbp7/8 Insulin-Like Growth Factor Binding Protein 7 
16323 Inhba Activin 
20692 Sparc Osteonectin 
17228 Cma1 Chymase 
641340 Nrbf2 Nuclear receptor binding factor 2 
17227 Mcpt4 Mcpt4  mast cell protease 4  
20379 Sfrp4 Secreted frizzled-related protein 4 
14129 Fcgr1 Fc Fragment Of IgG, High Affinity Ia, Receptor (CD64) 
22339 Vegfa Vascular endothelial growth factor A 
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3.1 Ameliorated colitis in mice lacking GPR4 or OGR1 
 
This is the first study in which the role of pH sensing G-protein coupled 
receptors and intestinal inflammation was studied in some detail. Taken 
together, the results demonstrated that GPR4 knockout mice had a 
partially reduced susceptibility in the DSS induced chronic colitis model.  
The deficiency of the pH receptors GPR4 and OGR1 attenuated 
spontaneous inflammation and modulated the severity of disease in the 
IL-10 -/- mouse model, indicating an important pathophysiological role for 
these G-protein coupled receptors during the pathogenesis of mucosal 
inflammation. 
 
In the model of chronic DSS induced colitis, resembling UC, Gpr4 -/- mice 
showed less body weight loss and lower histology scores compared with 
wildtype littermates, suggesting less severe inflammation. In contrast, 
we also observed shortening of colon length and higher colonoscopy 
scores in Gpr4 -/- mice during DSS administration consistent with more 
severe inflammation. No significant difference was observed in MPO 
activity, spleen weight and cytokines expression between Gpr4 +/+ and 
Gpr4 -/- mice group. Despite these apparently discrepant observations, 
the overall clinical picture suggests an improvement of colitis since the 
major indicators such as body weight and histology score were in favor of 
an improved course of disease. The reasons for these discrepancies are 
currently unclear but might be related to presence or absence and 
specific functions of the receptor in the different cell types forming the 
intestinal mucosa. Cell-specific knock-out of GPR4 may help to address 
this point. Moreover, the susceptibility to DSS highly varies between 
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animal species and mouse strains 93. The C57BL/J6 strain of mice was 
found to be more susceptible to DSS induced colitis than the Balb/c 
strain 93. We emphasize that we have consistently observed the same 
tendency and unbiased results in all three round of DSS induced chronic 
colitis (2 rounds of Balb/c and 1 round of C57BL/J6 background). 
 
To further investigate the role of pH receptors, another IBD mouse model, 
the spontaneous colitis model, simulating CD, was introduced into the 
study. Kaplan-Meier analysis of prolaps onset showed that the deficiency 
of GPR4 or OGR1 significantly delayed the onset of rectal prolapses in 
female Gpr4 +/+ /Ogr1 -/- /IL-10 -/- and male & female Gpr4 -/- /Ogr1 +/+ 
/IL-10 -/- mice rather than Gpr4 +/+ /Ogr1 +/+ /IL-10 -/- mice, which was 
consistent with the protective role of deficient pH receptor. The finding 
was also supported by lower histology scores and MPO activity 
measurements. 
 
The LPLs profiles in flow cytometric analysis showed that GPR4 knockout 
suppressed infiltration of CD4+ (T helper) cells, mainly as Th1 cells, but 
not CD8+ (T cytotoxic) cells, which were confirmed by the cytokine mRNA 
expression data. Female Gpr4 -/- /Ogr1 +/+ /IL-10 -/- mice had a 
significantly lower Th1 cytokine IFN-γ mRNA expression in colon 
compared with female Gpr4 +/+ /Ogr1 +/+ /IL-10 -/- counterparts. IL-10 is a 
well-known anti-inflammatory cytokine and suppressor for Th1 cells and 
macrophages 94. IL-10 -/- mice undoubtedly have a high level of Th1 cells 
86, 88, 89. But our data showed Gpr4 -/- /Ogr1 +/+ /IL-10 -/- mice had a 
surprisingly low CD4+ T helper cells infiltration with significantly low 
IFN-γ expression, suggesting strong suppression of Th1 cells by the lack 
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of GPR4. Depleting GPR4 signaling replaced IL-10 to suppress Th1 cells or 
blocked the pathway of Th1 cells infiltration in Gpr4 -/- /Ogr1 +/+ /IL-10 -/- 
mice. Last, the anti-inflammatory effect of GPR4 deficiency seems not to 
be mediated by elevating Treg levels and enhancing its suppression 
because no significant changes in Treg were observed among Gpr4 +/+ 
/Ogr1 +/+ /IL-10 +/+, Gpr4 +/+ /Ogr1 +/+ /IL-10 -/- and Gpr4 -/- /Ogr1 +/+ /IL-10 
-/- mice.  
 
 
3.2 The proposed mechanism of GPR4 mediated 
inflammation aggravation 
 
Based on the above findings, the possible mechanism of GPR4-mediated 
inflammation aggravation is proposed (Figure 11). In spontaneous colitis 
model, the additional deletion of GPR4 in IL-10 -/- mice leads to the loss 
of the proton sensors and defective downstream signaling pathway; 
induces suppression of Th1 cells and less production of IFN-γ in colon; 
offers protection against spontaneous inflammation; and finally delays 
the onset of rectal prolapse. Therefore, in turn, activation of GPR4 is 
likely to exacerbate intestinal inflammation and trigger the responses 
which promote inflammation via a Gs-cAMP-Th1-IFN-γ pathway. IFN-γ is 
widely known to aggravate inflammation by increasing inducible Nitric 
Oxide Synthase (iNOS) expression, activating macrophage and NK cells 
and inducing apoptosis 96, 97. The excessive production of glycolytic 
metabolites in inflamed tissues may cause the accumulation of protons, 
which further activates GPR4, forming a positive feedback loop.  
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Figure 11 The proposed mechanism of GPR4 mediated inflammation 
aggravation. The excessive production of glycolytic metabolites in 
colonic tissue leads to the accumulation of proton, which in turn 
activates GPR4, forming a positive feedback loop. Therefore, activation 
of GPR4 is likely to exacerbate intestinal inflammation and trigger the 
responses that promote inflammation. 
 
 
3.3 Several lines of evidence to support the 
destructive role of activated GPR4 in the progression 
of inflammation 
 
The mRNA expression of GPR4 or OGR1 in human colon tissues 
provides a theoretical foundation for the functional involvement. The 
over-expression of GPR4 in variety of human cancer tissues including 
colon cancer has been reported 71. In normal subjects, GPR4 mRNA is 
widely expressed. In small intestine and colon tissue, GPR4 shows a 
median expression level, as indicated by data provided by the National 
Center for Biotechnology Information (NCBI) Gene Expression Omnibus 
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(GEO) profile and Gene database 
(http://www.ncbi.nlm.nih.gov/sites/geo) and the BioGPS database of 
The Scripps Research Institute (http://biogps.org). Further evidence 
that GPR4 mRNA is strongly expressed in IBD patient’s colon tissues 
was generated by our group and web-shared data (GEO Profile 
database ID: 12504653 and 4234799). Interestingly, GPR4 abundance in 
CD patients with remission, but not in severe and moderate CD or UC 
patients, was found to be significantly higher than the normal control 
level. 
 
Recent publications on Gpr4 -/- mice have reported several evidences to 
support the destructive role of activated GPR4 in the progress of 
inflammation. Seuwen and coworkers reported 73, 98, that Gpr4 -/- mice 
showed an impaired response to VEGF-driven angiogenesis in a VEGF 
implant model and reduced tumor growth ability in a tumor-implant 
mouse model. Moreover, both GPR4 knockout and GPR4 inhibition by 
specific siRNAs resulted in decreased VEGFR2 (VEGF receptor 2, the main 
signaling receptor for VEGF on endothelial cells) levels, which might be 
one of the reasons for the reduced angiogenic response to VEGF 73, 98. In 
an antigen induced arthritis mouse model, GPR4 deficient mice showed 
a significant inhibition of knee swelling and reduced severity of arthritis 
98. Also, reduced immune responses and attenuated airway 
hyperresponsiveness were observed in GPR4 deficient mice following 
ovalbumin exposure 98. In the same ovalbumin-induced asthma mouse 
model, the decreased airway hyperresponsiveness in Gpr4 -/- mice was 
associated with the reduction in the number of eosinophiles in 
bronchoalveolar lavage fluid, indicating a strong correlation between 
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GPR4 deficiency and inflammation inhibition 99. In the cigarette 
smoke-induced COPD mouse model,  Gpr4 -/- mice showed an 
accelerated elimination of airway inflammation and enhanced neutrophil 
resolution 100, which, again, supports our observations.  
 
 
3.4 Progress in GPR4 downstream signaling pathway 
studies 
 
Up to date, only few efforts had been made to elucidate the GPR4 
signaling pathway. Yang et al showed that acidosis/GPR4 signaling 
regulates endothelial cell adhesion mainly through the Gs/cAMP/Epac 
pathway 43. The authors reported that the activation of GPR4 by acidosis 
increased the expression of multiple adhesion molecules such as 
E-selectin (SELE), Vascular cell adhesion molecule 1 (VCAM-1) and 
Intercellular Adhesion Molecule 1 (ICAM-1) in vitro and increased the 
adhesiveness of human umbilical vein endothelial cells (HUVECs) 
expressing endogenous GPR4 43. The mentioned adhesion molecules 
help  to facilitate the binding of leukocytes and exacerbate the vascular 
inflammatory response. In our data, Gpr4 -/- /IL-10 -/- female mice 
showed lower mRNA expression in iNOS, TNF-α, IFN-γ, IL-6, MCP-1, 
CXCL2, CXCL1, SELE and VCAM-1 rather than Gpr4 +/+ /IL-10 -/- female 
mice (no statistical significance except for IFN-γ), which at least in part is 
in agreement with the observations. The transcriptome analysis from the 
same research group reported that the NF-κB pathway was important for 
the acidosis and aGPR4-induced inflammatory gene expression 101.  
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Other data link GPR4 to the Extracellular Signal Regulated Kinase 1 and 2 
(ERK 1/2) pathway. Bektas et al reported that activated GPR4 inhibited 
epidermal growth factor (EGF) induced ERK 1/2 activation 102. But GPR4 
was activated by the controversial agonist SPC, so the validity of this 
study must be questioned. Martinez et al reported that extracellular 
acidification induced human neutrophil activation through the activation 
of the P13K/Akt and ERK pathway, and low pH intensified acute 
inflammatory responses by delaying spontaneous apoptosis of 
neutrophil and extending the neutrophil functional lifespan 44, 45. GPR4 
may be among the mediators which are responsible for the acidification 
induced neutrophil activation. However, the presence of GPR4 has not 
been shown in these cells up to date. Considering other GPCRs, e.g. 
TDAG8 72, angiotensin II type 2 receptor 103, 104 and 
sphingosine-1-phosphate receptor (S1P5) 105, also link to ERK pathway; 
Thus, the ERK pathway might be involved or partially involved in GPR4 
signaling transduction and ultimately aggravate inflammation in an acidic 
environment. There are also some clues to link the ERK pathway  to 
another pH sensing receptor, OGR1. An independent work reported low 
pH induced calcium mobilization and ERK phosphorylation in cancer 
progression 106. Another work from a Japanese group reported 
extracellular acidosis induced IL-6 production and calcium mobilization, 
associated with the phosphorylation of ERK and p38MAPK 107. The 
authors argued that it might be OGR1, but not GPR4, being responsible 
for the phosphorylation of ERK and Gq protein activation with calcium 
mobilization in response to extracellular protons.  
 
cAMP has long been recognized as a “turn off button” and an 
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immunosuppressor to inhibit T cell functions 108, 109. But recent studies 
demonstrated that cAMP also promotes T cell subset differentiation and 
T cell mediated immunity 110. A conditional cAMP deficiency mouse 
model, in which the stimulatory Gα subunit (Gαs) was deleted in T cell, 
demonstrated that isolated CD4+ T cell had reduced cAMP levels, fewer 
IFN-γ and IL-17 production, a weak Th1 and Th17 response but normal 
Th2 and Treg responses both in vitro and in vivo. The isolated CD4+ T cell 
from same mouse model, short of cAMP production, showed reduced 
Th1/Th17 cell differentiation in vitro, and failed to induce colitis in the 
adoptive transfer mouse model (Rag1 -/- recipients). The data provide 
further evidence for the contribution of cAMP to inflammation 
development, at least partially, supports the proposed mechanism of a 
GPR4-mediated inflammation aggravation and Gs-cAMP-Th1-IFN-γ 
pathway.  
 
On all accounts, because there is a massive functional crosstalk among 
GPCRs, cAMP, Th1 cells, IFN-γ, other cytokines, kinases, transcription 
factors and promoters involved 96, 97, further analysis of downstream 
signaling networks of GPR4 will be of importance to elucidate the 
mechanisms underlying GPR4-mediated inflammation aggravation, as 
well as the complexity of the cytokine network in human IBD. 
 
 
3.5 Progress in development of GPR4 inhibitors 
 
A forward thinking strategy would also be to develop specific inhibitors 
or down-regulation modulators for IBD treatment. So far, two GPR4 
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inhibition agents were recently patented by Novartis 98, 111.  
 
GPR4 antagonists, a group of imidazo-pyridine derivatives, were recently 
recognized and published 111. For example: 2-Ethyl-3-{4-[3-(4-isopropyl- 
piperazin-1-yl)-prop-1-ynyl]-benzyl}-5- ,7-dimethyl-3H-imidazo[4,5-b] 
pyridine. The patent claimed to treat diseases and disorders which cover 
angiogenesis and/or pain, including autoimmune and inflammatory 
diseases using the compounds 111. 
 
Another inhibitory modulator is siRNA specific for GPR4 98. The claims 
covered the treatment of cancer, anti-angiogenesis, macular 
degeneration, psoriasis, arthritis, multiple sclerosis or atherosclerosis by 
the inhibition of GPR4 98. 
 
 
3.6 OGR1 and inflammation 
 
In agreement with our findings, there are several publications which 
describe the contribution of OGR1 to inflammation. Further, very 
interesting, OGR1 signaling transduction seems to be totally different 
from GPR4. Aoki et al 112, 113 reported Ogr1 -/- mice exhibit diminished 
airway inflammation in the ovalbumin-induced asthma mouse model, 
including reduction in eosinophilia and mucus production, less goblet 
cell hyperplasia and significantly attenuated airway hyperresponsiveness. 
The diminished inflammation was achieved through Th2 responses, but 
not Th1 as in GPR4 deficient mice, because the Ogr1 -/- mice showed 
impaired ability to generate Th2 associated cytokines IL-5, IL-4 and IgE 113. 
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A parallel project in our group has shown that OGR1 expression in Mono 
Mac 6 cells (derived from human macrophages and monocytes) was 
found to be induced by TNF-α, but not by other cytokines (IFN-γ, IL-1β, 
IL-6 and TGF-β), and the induction was reversed by NF-kB inhibitors  
(Cheryl de Valliere, unpublished data), further proving that OGR1 
signaling differs from GPR4. Other publications associated OGR1 
signaling with cyclooxygenase-2 (COX-2). Tomura et al 114 reported that 
protons/OGR1 signaling induced COX-2 expression and subsequent 
prostaglandin E-2 (PGE2) production through Gq/11/phospholipase 
C/protein kinase C pathways, resulting bone calcium release and 
depletion. The effect was reversed by small interfering RNA (siRNA) 
specific to OGR1 and specific inhibitors for intracellular signaling 
pathways 114. Liu et al reported activated OGR1 induced COX-2 expression, 
PGI2 production and MKP-1 expression 115. But in our data, we did not 
observe any change in COX-2 mRNA expression in both male and female 
Gpr4 +/+ /Ogr1 -/- /IL-10 -/- mice . How exactly the activated OGR1 boosts 
inflammation needs further efforts to resolve in the near future.                         
 
 
3.7 Gender dependent effect of OGR1  
 
The gender difference exists also in immune response. The stronger 
response in female provides a better protection against infection, but 
may contribute to the higher incidence of autoimmune disease, e.g. 
Systemic lupus erythematosus (SLE), Rheumatoid arthritis (RA), Systemic 
sclerosis (SSc), rather than in male. The possible reasons for the gender 
difference are sex hormones or factors, including estrogen, testosterone 
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and Chromosome X, influencing the development, maturation, activation 
and apoptosis of immune cells. Unlike these female prevalent 
autoimmune diseases, as mentioned in Chapter 2.1, there seems to be 
only a slightly gender related difference in IBD incidence. UC is slightly 
more common in males, whereas CD shows a small female 
predominance 27. 
 
By chance, we observed an obvious in-vivo gender difference in the 
spontaneous IBD mouse model. As shown in our data, the prolapse 
incidence in Gpr4 +/+ /Ogr1 -/- /IL-10 -/- male mice was significantly higher 
than in its female counterparts and Kaplan-Meier prolaps onset analysis 
showed that the onset of rectal prolapse in Gpr4 +/+ /Ogr1 -/- /IL-10 -/- 
female mice was significantly delayed as compared to their male litter 
mates, while no difference was observed in male and female mice for 
both Gpr4 +/+ /Ogr1 +/+ /IL-10 -/- and Gpr4 -/- /Ogr1 +/+ /IL-10 -/- groups. The 
reason for the gender difference in prolapse incidence of Gpr4 +/+ /Ogr1 
-/- /IL-10 -/- mice is not yet clear.  
 
At the moment, we do not know whether sex hormones interfer with the 
regulation of OGR1 signalling pathways, or even if GPR4 and OGR1, 
respectively, are involved in different IBD types, UC and CD. More 
research work needs to be done to ascertain the involvement and role of 
estrogens, testosterone or other sex-based mediators in OGR1 signalling 
pathway.  
 
 
3.8 Other proton sensors and the digestive system 
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pH receptors are not the only pH-sensing mechanism. Other than proton 
sensing GPCRs, there are many other receptors, enzymes, kinases and 
transporters functioning as sensors and regulators of extra- and 
intracellular protons 116, which also play important roles to maintain pH 
homeostasis, such as Na+/H+ exchanger (NHE family), Na+/HCO3- 
transporters (biocarbonate transporters), acid sensing ion channels 
(ASICs), V-ATPases and so on.  
 
A few representative members important for the digestive system are 
being shown here 116. The Na+/H+ exchanger isoform 2 (SLC9A2/NHE2) is 
widely expressed in multiple tissues and responsible for fluid secretion in 
the digestive system 117, 118. Na+/H+ exchanger isoform 3 (SLC9A3/NHE3) 
has a high abundance in kidney and intestines, and renal and intestinal 
absorption is defective in mice lacking SLC9A3/NHE3 119, 120. Diarrhea is 
the direct result of pathological SLC9A3/NHE3. Na+/H+ exchanger isoform 
4 (SLC9A4/NHE4), a recognized risk loci for IBD 36, is abundantly 
expressed on stomach and kidney, whose pathophysiology is now being 
better understood. Histological analysis revealed that SLC9A4/NHE4 -/- 
mice were hypochlorhydric with reduced numbers of parietal cells and a 
loss of mature chief cells, indicating loss of SLC9A4/NHE4 corresponding 
to the impaired gastric acid secretion 121, 122.  
 
Another kind of intracellular pH regulator is the mammalian bicarbonate 
transporter, which functions as acid extruder or acid loader to regulate 
intracellular protons. The acid extruding HCO3- transporters translocate 
Na+ and HCO3- together in the same direction. Because the large 
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transmembrane Na+ gradient is in favor of the net influx of HCO3-, which 
is equivalent to acid extrusion from the cells. For example, Na+/HCO3- 
co-transporters SLC4a4/NBCe1 deficiency led to severe metabolic 
acidosis and intestinal obstruction 123, 124. The acid loading Cl-/HCO3- 
exchanger deal with the exchange of Cl- for HCO3-. The inward Cl- gradient 
provides the driving force for net HCO3- efflux in normal conditions. 
However, Cl-/HCO3- exchanger SLC26a3/DRA’s murin null phonotype 
showed a high chloride diarrhea and acidic luminal content in the colon 
125. Being of considerable interest, SLC26a3/DRA, predominantly 
expressed in the digestive system 126, 127, particularly abundant in 
duodenum and colon, was also identified as a risk loci for IBD 36 and its 
mutations caused congenital chloride diarrhea (CLD) 128-130.  
 
We cannot rule out the involvement of any other proton 
sensor/transporter in the development of IBD. They may also 
compensate for GPR4 or OGR1. The previous work from our group 
reported that the pH sensitive kinase Pyk2 was upregulated in the 
proximal tubule of Ogr1 -/- mice 79. And GPR4 or OGR1 may regulate the 
activity and function of other proton sensors/transporters. A study 
demonstrated that chronic acidosis and GPR4 up-regulated the 
H+-K+-ATPase α subunit (HKα2) protein in HEK293 cells 78. The previous 
work from our group also showed that OGR1 regulated the activity of 
two major plasma membrane proton transporters in HEK293 cells and 
renal proximal tubules, Na+/H+ exchanger (NHE3) and H+-ATPase 79. 
Together with pH receptors, they may operate through complex 
interactions with each other.   
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Chapter 4  
Future Perspectives 
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Some further areas of work come out as a consequence of our results: 
 
 In this thesis, we firstly recognized that Gpr4 -/- mice had a diminished 
mucosal inflammation by decreasing Th1 response and IFN-γ 
production. The reduced IFN-γ mRNA expression was shown in colon 
tissue of female Gpr4 -/- /Ogr1 +/+ /IL-10 -/- mice, but the IFN-γ protein 
level expression has not been tested yet. Therefore, the protein level 
expression of IFN-γ should be determined, e.g. by western blotting or 
ELISA.  
 The intracellular cytokines could also be measured by intracellular 
cytokine staining of LPLs and FACS. Th1 associated cytokines (e.g. 
IFN-γ and IL-2) and Th2 cytokines (e.g. IL-4 and IL-10) staining could 
be measured, respectively, and Th1/Th2 ratio could be analyzed to 
verify GPR4 mediated inflammation aggravation through Th1 
pathway.  
 The protein level of GPR4 or OGR1 expression in human colon tissues 
could be validated by western blotting or immunofluorescence if 
corresponding antibodies would be available.  
 It is necessary to test the in vivo anti-inflammatory properties of 
specific GPR4 antagonists in DSS induced chronic colitis mouse model 
and the spontaneous colitis mouse model. 
 It is also necessary to test the proinflammatory effects of GPR4 or 
OGR1 activation with protons or other specific agonists in mouse 
colon, if these agonists are available.  
 More in-vitro studies from GPR4 overexpressing cell lines would help 
to ascertain more detailed information on GPR4 activation as well as 
its downstream signaling pathway.  
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 The development and application of proton sensing receptors 
knockin mice (transgenic overexpression) would contribute to our 
better understanding of the molecular mechanism underlying pH 
receptor mediated inflammation aggravation.    
 In this thesis, we observed an obvious gender difference in prolapse 
incidence and inflammatory progression in Gpr4 +/+ /Ogr1 -/- /IL-10 -/- 
mice group, while no difference existed for male and female mice for 
Gpr4 +/+ /Ogr1 +/+ /IL-10 -/- and Gpr4 -/- /Ogr1 +/+ /IL-10 -/- mouse 
groups. More research work needs to be done to ascertain the 
involvement and role of estrogens, testosterone or other sex-based 
mediators in OGR1 signalling pathways. 
 We investigated pH receptors GPR4 and OGR1 in this thesis. Another 
member of proton sensing receptor family, TDAG8, has not been 
studied in IBD. Especially, TDAG8 has been recognized as a risk locus 
in GWAS studies, which means it might play an even greater role in 
IBD pathogenesis. All the mentioned methodologies could be applied 
to TDAG8 studies, to further elucidate the precise role of TDAG8 in 
inflammation. 
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